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Abstract 
Small diameter (< 6 mm) vascular grafts suffer from serious deleterious effects not 
encountered with their larger diameter relatives, leading to premature graft failure 
through restenosis. Platelet activation, inflammation, and smooth muscle cell 
proliferation are leading contributors to thrombosis and neointimal hyperplasia, both 
contributors to the progression of restenosis. It may be possible to suppress negative 
biological responses to vascular implants through the modification of surface properties 
and incorporation of drug release into blood contacting materials. In this work, 
bioengineering approaches are presented to improve the biocompatibility of small 
diameter vascular grafts. 
We demonstrate a novel engineering approach for incorporating natural, decollagenized 
elastin matrices into PEU 1074A reinforced vascular grafts through spray-coating and 
electrospinning processes in a manner that retains elastin’s excellent blood contacting 
properties. A vascular construct with excellent mechanical and surgical handling 
properties demonstrating the suppression of neointimal hyperplasia is presented after 21 
days in vivo. 
Nitric oxide (NO) has been investigated over the past several decades due to its platelet, 
inflammation, and smooth muscle cell suppressing effects; and if appropriately delivered, 
could positively mediate the contributors to restenosis. Here, we characterize a novel 
macrocyclic NO donor developed by linking S-nitroso-N-acetyl-D-penicillamine (SNAP) 
directly to 1,4,8,11-tetraazacyclotetradecane (cyclam). Here, we present characterization 
data for SNAP-Cyclam and demonstrate stable, long term NO release at physiologically 
relevant levels for more than 90 days when incorporated into poly(˪-lactic acid) films. 
Transition metals, such as copper and iron, are known to initiate NO production from S-
nitrosothiols. It is reported in this work that additional transition metal ions; Co2+, Ni2+, 
and Zn2+, which have not been reported to generate NO from RSNOs have the capacity to 
generate NO from the S-nitrosothiol, S-nitroso-N-acetyl-D-penicillamine. In vivo data 
alludes to the possibility that Zn2+ may be able to generate NO from endogenous donors 
and provide beneficial effects. 
These three novel developments form the basis for the potential construction of clinically 
relevant small diameter vascular grafts capable of suppressing the deleterious effects, 
namely thrombosis and neointimal hyperplasia, commonly encountered in current small 
diameter vascular grafts.
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Chapter 1: Introduction to Nitric Oxide 
 
1.1. Background of Nitric Oxide 
Nitric oxide’s (NO) physiological presence was first theorized in the 16th and 17th 
centuries, but it wasn’t until the 1970’s that Ferid Murad began investigating vasodilators 
and their effect on guanylate cyclase activity1. Around 1986, NO and endothelium 
derived relaxing factor (EDRF) were theorized simultaneously as the same molecule by 
Ignarro et al. and Furchgott et. al1-2. In 1987, NO was positively identified as EDRF by 
Ignarro et. al1-6. All three scientists were awarded the Nobel Prizes in 1998 for their 
discovery of the NO/EDRF association. 
NO is a free radical (•N=O), lipophilic gas under standard atmospheric conditions with a 
bond length of 1.15 Å7-8. In its ground state, NO contains a single electron in its 2p-π 
antibonding orbital. A loss of this electron results in the formation of a nitrosonium 
cation (NO+), while an additional electron added to the antibonding orbital elicits a 
nitroxyl anion (NOˉ)3, 7, 9-10. The presence of an unpaired electron gives NO the ability to 
react with oxygen (O2), superoxide (O2ˉ), and transition metals3, 7. Coupled with the 
reactive nature of thiols, the formation of S-nitrosothiols (RSNOs) from NO is highly 
favored in biological systems7. 
As a free radical, NO was perceived as a physiologically toxic substance prior to its link 
to EDRF. This was in part due to the typical weak intermolecular forces of other 
signaling molecules, which were not believed to be applicable to NO. However, NO 
mediated by guanosine 3’,5’-cyclic monophosphate (cGMP) binds to the iron containing 
heme group of soluble guanylate cyclase (sGC) in a metal-nitrosyl complex coupling 
with several factors including cGMP-dependent protein kinase-G5, 11. In the absence of 
cGMP, NO can act in low concentrations through interactions with complexes containing 
transition metals. Reactions between NO and the thiyl radical (RS•) readily produce S-
nitrosothiols (Equation 1)12. This mechanism of formation may be responsible for the 
formation of protein based S-nitrosothiols in the presence of NO12. In addition, NO can 
mediate cell signaling through the formation of S-nitrosothiols by the S-nitrosylation of 
cysteine residues, shown to regulate the activity of proteins involved in cellular 
regulation5, 13. 
  (1) 
 
Since its discovery, the understanding of NO’s functions within the body have expanded 
significantly to include roles in almost every major system. NO maintains several diverse 
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functions throughout the body, including intercellular signaling14-15, immune response 
and platelet aggregation16-19, wound repair5, 19-20, nervous system function21, respiration5, 
22,  and vascular regulation19, 23-28. In low concentrations, NO functions as a signal 
transducer within the physiological environment5. Importantly, metabolites of NO 
including nitrites, nitrates, and S-nitrosothiols are mediators of its cytotoxic or 
cytoprotective effects, and have been shown to regulate cellular apoptosis and necrosis, 
protein and deoxyribonucleic acid (DNA) damage, and inhibition of mitochondrial 
respiration5, 29. Due to the extensive involvement of NO in physiological functions, 
deficiencies in its synthesis and delivery have been linked to many diseases30-31. 
1.2. Physiological Production of Nitric Oxide 
Endogenous NO is produced enzymatically through several classes of homodimers 
known as nitric oxide synthases (NOS)3, 11, 13, 32-35. To accomplish this, the amino acid L-
arginine is catalyzed through sequential, five electron oxidation into L-citrulline and NO 
in a calmodulin (CaM) dependent response to physiological stimuli with the involvement 
of nicotinamide-adenine-dinucleotide phosphate (NADPH) and molecular oxygen 
(Figure 1.1)3, 13, 33, 35-36. Three isoforms of NOS have been indentified: nNOS (NOS 1; 
neuronal), iNOS (NOS 2; inducible), and eNOS (NOS 3; endothelial)3, 6, 13, 34, 36-40. Table 
1.1 lists their corresponding properties. 
 
Figure 1.1. Physiological production of nitric oxide from L-arginine. Figure 1.1 shows the production 
of nitric oxide and L-citrulline from L-arginine. Production occurs via nitric oxide synthases (NOSs). 
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Table 1.1. Summary of nitric oxide synthase enzyme properties. Table 1.1 summarizes the nitric 
oxide synthase isoforms and their relevant properties.
 nNOS iNOS eNOS 
Gene NOS 1 NOS 2 NOS 3 
Mass 130 kDa 150–160 kDa 135 kDa 
Type 
 
Constitutive 
 
 
Inducible 
 
 
Constitutive 
 
Regulation Ca
2+ Dependent 
 
• Transcriptional 
Regulation 
• Ca2+ Independent 
• Ca2+ Dependent 
• Phosphorylation 
Location • Nervous Tissue • Skeletal Muscle 
• Immune System 
• Cardiovascular 
System 
Endothelium 
 
Function 
 
• Neurotransmission 
• Potentiation 
• Inflammation 
• Host Defense 
 
• Platelet Inhibition 
• Inhibition of SMC 
Proliferation 
• Regulation of 
Vascular Tone 
 
NO 
Production Low, transient levels 
High, limited 
duration 
Low, transient 
levels 
 
The three isoforms maintain an amino acid sequence similarity of 55%34. The factors 
influencing the generation of NO from NOSs are shown in Figure 1.2. 
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Figure 1.2. Factors affecting physiological nitric oxide production. Figure 1.2 shows the factors 
influencing the production of NO from the NOS isoforms. 
nNOS is responsible for the production of NO in macrophages during inflammation and 
phagocytosis, resulting in the macrophages cytotoxic properties11, 33. nNOS is expressed 
within certain neurons in the brain and has recently been implicated in regulating 
functions such as learning and memory. In the central nervous system, nNOS mediates 
long-term potentiation and inhibition of synaptic signals33. The most well-known 
activator of nNOS is lipopolysaccharide (LPS), produced by gram negative bacteria, 
specifically Escherichia Coli, during sepsis34. nNOS is also activated by the presence of 
L-arginine and one or more inflammatory cytokines including tumor necrosis factor-α 
(TNF-α), interferon gamma (IFN-ϒ), and interleukin-1 (IL-1)13, 34. Additionally, the 
activity of iNOS can be down regulated through peroxynitrite-mediated nitration, 
decreasing its catalytic activity13.  
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iNOS, first characterized in macrophages and termed inducible NOS, is not usually 
present within cells. Though it is generally associated with macrophages, any cell is 
capable of expressing iNOS given that the requisite inducing agent is present33, 41. Unlike 
eNOS and nNOS, iNOS is constantly active and does not have a dependency on 
intracellular Ca2+ concentration, as it is permanently bound to CaM due to its high 
binding affinity even at low intracellular calcium concentrations5, 11, 13.  
eNOS is usually found within the endothelium, but has been detected in other cell types 
such as cardiomyocytes, platelets, and neurons. eNOS, unlike nNOS, can be upregulated 
by increased fluid shear stress due to blood flow by phosphorylation of its reductase 
domains3, 34, 42.  
eNOS and nNOS are referred to as constitutive NOSs, and are generally dormant under 
normal physiological conditions34, 37. eNOS and nNOS are capable of producing 
nanomolar concentrations of NO over relatively short time periods, whereas iNOS is able 
to produce micromolar concentrations over longer time periods, on the order of hours to 
days, which matches their respective physiological functions5. Differing from iNOS, 
eNOS and nNOS synthesize NO in a periodic manner. The production of NO by eNOS 
and nNOS is regulated by a Ca2+ dependent CaM pathway3, 33-34, 40-41, where activation of 
CaM is heavily dependent on intracellular calcium levels. Acetylcholine has been found 
to increase intracellular Ca2+ concentrations in endothelial cells13. A conformational 
change in flavin mononucleotide (FMN) post-CaM activation results in NO synthesis by 
eNOS and nNOS5. 
1.3. Physiological Reactions of Nitric Oxide 
In the physiological environment, NO is capable of reacting with transition metals, 
oxygen, and superoxide, among others. Common products generated from these reactions 
include metal-nitrosyl compounds, nitrogen oxides, and peroxynitrites, respectively3, 11, 
13. The three main contributors to the formation of metal-nitrosyl complexes during 
interactions with NO are copper, iron, and zinc13. Enzymatic regulation is possible 
through interactions of NO with transition metals present in the enzyme or associated 
proteins13. NO acts on sGC in a reaction with its ferrous heme center to convert 
guanosine-5ˈ-phosphate (GTP) into cGMP, by forming a ferrous-nitrosyl-heme complex3, 
13. Even low concentrations (< 100 nM) of NO are capable of activating sGC. Activation 
of sGC can lead to a 400–500 fold increase in the rate of cGMP synthesis13, 43. 
Mitochondrial respiration is inhibited by NO through a reversible reaction with 
cytochrome c oxidase (CcO), responsible for mitochondrial adenosine triphosphate 
(ATP) synthesis44-45. CcO contains two heme moieties and two Cu2+ centers13. 
Due to NO’s existence as a free radical gas, its unpaired electron is capable of interacting 
with other reactive oxygen species (ROS). ROSs, in low concentration, are believed to 
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play key roles in the physiological environment, including regulation of cell signaling 
and gene expression46. Conversely, high levels of ROSs can contribute to vascular 
dysfunction, inhibited cellular proliferation and growth, as well as genetic damage46. 
These reactions are briefly discussed below. 
NO is able to react with molecular oxygen, and as O2 is a triplet molecule, it is favored to 
react with molecules containing unpaired electrons, such as NO. The result of the 
reaction between NO and O2 produces NO2ˉ, with intermediates of N2O3, nitrosonium 
(NO+) and NO2 3, 11, 13, 47-50. This reaction scheme is shown in equations 2.1–2.4. The lipid 
bilayer is a probable site for the reaction between NO and O2, as both are preferentially 
drawn to the hydrophobic environment12. The conversion of NO and O2 into N2O3 is 
termed NO autoxidation13. These intermediates are believed to be involved in S-
nitrosation through the nitrosolation of the nitrosonium intermediate with thiols, 
secondary amines, and phenolics13, 51. This autoxidation is heavily dependent on the 
concentrations of NO and O2, which result in high concentrations of N2O3 at the reaction 
site. N2O3 has been implicated in the alkylation of DNA through the formation of N-
nitrosoamines52. The reaction kinetics from NO to NO2ˉ is a third order, rate determining 
reaction13. NO can react with oxygenated hemoglobin (Hb) to produce methemoglobin 
(metHb) (Equation 3) and with deoxygenated Hb to produce S-nitrosohemoglobin 
(SNOHb)53. 
  (2.1) 
  (2.2) 
  (2.3) 
  (2.4) 
    (3) 
 
Reactions of NO with other physiological radicals proceed in a nearly diffusion rate-
controlled manner. In addition, NO is the least reactive of all the free radicals present in 
the physiological environment, endowing NO with antioxidant properties11. The 
superoxide anion, O2ˉ, interacts with NO to form peroxynitrite (ONOOˉ) in a rapid, 
diffusion rate limited reaction3, 49, 54. This reaction is shown in Equation 411. 
  (4) 
 
7 
 
Peroxynitrite is a highly reactive molecule, though not a free radical55, thought to be 
produced in mitochondria and immune cells13, 55. The intermediate of peroxynitrite, 
ONOOH•, is thought to be capable of nitrating and oxidizing lipids, proteins, and 
nucleotides, causing irreparable damage to DNA and protein structures13, 55. It has been 
theorized that single strand DNA damage as a result of elevated peroxynitrite formation 
can be linked to attacks on DNA’s sugar-phosphate backbone52. Reactions with 
superoxide in the formation of peroxynitrite may limit the amount of physiological NO 
available, as this reaction is not reversible53. Equimolar ratios of NO and superoxide are 
favored for the production of peroxynitrite3. In addition, overproduction of peroxynitrite 
has been implicated in cellular apoptosis and necrosis13.  
One of the largest sources of superoxide is located in the inner mitochondrial membrane, 
as incomplete respiration causes molecular oxygen to be reduced54. In the cytosol, several 
enzymes catalyze the one electron reduction of oxygen to superoxide. Additional 
mechanisms for the formation of superoxide include oxidative decomposition of 
molecules, such as flavin adenine dinucleotide-hydroquinone form (FADH2)54. An 
important mechanism of superoxide production in the vasculature is the autoxidation of 
oxygenated Hb to its reduced metHb form54. Since superoxide has a shorter lifetime than 
NO, peroxynitrite is generated in areas adjacent to superoxide sources54.  
eNOS uncoupling can initiate the production of superoxide from eNOS rather than NO38, 
46. Several mechanisms can result in a phenomenon known as eNOS uncoupling, 
including a reduced bioavailability of tetrahydrobiopterin (BH4). This uncoupling 
reaction will propagate due to the continued production of superoxide. Superoxide 
generated during uncoupling reacts with NO to generate peroxynitrite, while NADPH 
oxidases participate in the cascade as a superoxide producer. In a similar cascade, 
overexpression of eNOS in the absence of a similar increase of BH4 can result in eNOS 
uncoupling due to a disproportionate amount of the enzyme in relation to the cofactor38. 
In physiological environments, peroxynitrite may exist in the anion form or acid form 
(ONOOˉ/ONOOH) (Equation 5)3, 11. Protonation of the acid form results in the 
production of the nitrate anion (Equation 6). Peroxynitrite reacts with physiologically 
present carbon dioxide (CO2) to form nitrosocarboxoperoxylate (ONOOCO2ˉ) (Equation 
7)54. ONOOCO2ˉ, a stronger nitrosating agent than peroxynitrite, has been shown to 
generate NO2• and CO3ˉ•, finally producing a nitronium ion (NO3) (Equation 8)3, 11, 54-58. 
Peroxynitrite is also able to react with free thiols to form disulfides and sulfenic acid 
(Equation 9). Peroxynitrite formation is more likely under infectious or inflammatory 
conditions in which high NO and O2ˉ• concentrations exist, increasing the reactions with 
CO2 and production of ONOOCO2ˉ 3, 11, 56-57. Under these conditions, NO2• and CO3ˉ• 
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are formed in higher relative quantities3, 11, 56-57. CO3ˉ• has been proven to form protein-
protein and DNA-DNA crosslinks, and has been implicated in the tissue damage 
associated with inflammatory and infectious states11, 59-60. 
  (5) 
 
 
(6) 
 
 
(7) 
 
 
(8) 
 
 
(9) 
 
The reaction between NO and the superoxide anion is three times as rapid as the activity 
of superoxide dismutase (SOD)13, 46. SOD decomposes superoxide to form molecular 
oxygen and hydrogen peroxide (Equation 10)42, depleting superoxide supplies required to 
form peroxynitrite while performing a vital antioxidant function13. Nitrite generation is a 
potential fate of NO in a reaction with •OH, formed as byproducts of hydroxyl radical 
formation from H2O2 produced from the dismutation of superoxide (Equation 11)3. Much 
like the NOS enzymes, three forms of SOD are physiologically present in humans: SOD 
1 (Cu-Zn-SOD) in the cytoplasm, SOD 2 (Mn-SOD) present in mitochondria, and SOD 3 
which is extracellular42, 46. SODs act to mediate the cytotoxic effects of superoxide46. 
Since the reaction between SOD and NO is the most efficient reaction known in the 
realm of NO chemistry, the biological half-life of NO is highly dependent on local SOD 
concentrations46. Physiological NO can be generated in sufficient quantities that its 
reaction with superoxide is able to exceed the capacity of endogenous SOD55. A critical 
function of SOD is to protect NO and NO-mediated signaling pathways46. The production 
of hydrogen peroxide by SOD likely contributes to intracellular signaling, as hydrogen 
peroxide is relatively stable and easily diffuses through cell membranes46. 
  (10) 
  (11) 
 
1.4. Physiological Transport of Nitric Oxide 
Though NO is both nonpolar and uncharged, it is shown to be reasonably soluble in 
aqueous solutions (1.9 mM at 298K; 1 atm)61. In hydrophobic solvents, its solubility 
increases by a factor of approximately 10 62. Transport of NO within physiological 
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systems has been theorized to occur through simple diffusion across the lipid bilayer11. In 
physiological buffer, the diffusion rate of NO is around 3300 μm2·s-1 63. In part, this 
permits NO to function intracellularly without being reliant on membrane transport 
proteins, while also being capable of passing into the intracellular space11. As a free 
radical gas, NO has an effective lifespan of less than 1 second in physiological 
environments due to its short half-life, which limits its activity to a radius of 
approximately 100 μm from its production source31, 64-66. The freedom of movement of 
NO makes it an extremely potent therapeutic agent as it can diffuse through tissue 
without external aids, will behave based on the generated concentration gradient, and its 
short half-life limits its activity within location adjacent to its production source. 
1.5. Concentration Effects of Nitric Oxide 
Interestingly, the level and duration of NO release has been demonstrated to have widely 
varying effects within the physiological environment, and NO has been classified as a 
bimodal agent for this reason5, 19. Overproduction of NO has been attributed to increased 
incidents of cancer4 and has been found to play a role in neuronal death following a 
cerebrovascular stroke67. High levels of NO have also been linked to depleted energy 
reserves due to inhibition of mitochondrial respiration and glycolysis, both vital cellular 
functions68-69. 
Though NO has shown promise as a cytotoxic agent to microbes, viruses, and tumor 
cells, high concentrations of NO can also negatively affect the surrounding environment 
and healthy organisms3, 33. When NO releasing materials are applied in vivo, the 
overproduction or excessive release of NO can damage neighboring cells and tissues 
through several mechanisms. Initially, NO can cause direct harm at elevated 
concentrations to cellular structures. As local concentrations of O2ˉ increase, NO 
concentrations are affected as the equilibrium shifts towards higher ONOOˉ 
concentrations, resulting in the suppression of NO activity33. 
Because it is a free radical, NO is capable of causing damage to healthy cells and tissue, 
especially during production by iNOS due to the significantly higher output as compared 
to the constitutive NOS isoforms. As a control for NO, large quantities of O2ˉ are 
generated in conjunction with NO. The two components then form ONOOˉ/ONOOH, 
which functions as a cytotoxic mediator to reduce the tissue damage associated with 
increased NO concentrations34, 70-71. Interestingly, cells responsible for the production of 
significant quantities of NO are not themselves harmed by its toxic effects. In 
macrophages, the expected cause of this self-protection is due to anti-oxidative systems72, 
whereas in endothelial cells, the elevated levels of intracellular calcium are thought to 
inhibit guanylate cyclase activity34, 73. 
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1.6. Endogenous Nitric Oxide Donors 
S-nitrosation of components endogenously present within the body can form stable NO 
donors. NO produced by the constitutive NOS enzymes is stored as a nitrosothiol in 
albumin, and may become physiologically active as S-nitrosoglutathione or S-
nitrosocysteine34, 74-75. To date, over 100 such substrates have been identified as being 
capable of S-nitrosation76.  
Indirect disulfide formation with reduced glutathione (GSH) forms S-nitrosoglutathione 
(GSNO), a reversible reaction12, 77. Direct redox reactions between GSH and NO are 
slow, and the formation of GSNO would follow the previously mentioned third order 
reaction between NO and molecular oxygen12, 78. GSNO has been thought to be critical 
for NO’s physiological functions12. GSNO has been shown to be more stable than S-
nitrosocysteine12. Studies have shown decreased susceptibility of GSNO to copper ion 
mediated decomposition than S-nitrosocysteine12. An additional mechanism of GSNO 
decomposition is through a trans-nitrosation reaction, where GSNO can donate its nitroso 
functional group to other free thiols (Equation 12)12.  
  (12) 
   
It has been theorized that the trans-nitrosation reaction, with a rate constant of 1–300 M-
1·s-1, is responsible for the biological activity of GSNO through the transfer of the nitroso 
group to a more labile molecule capable of moving through the cellular membrane. These 
trans-nitrosation reactions with intracellular components may be responsible for the 
reduced biological activity of GSNO12. S-nitrosation of cysteine is a post-translational, 
reversible process critical in the regulation of protein function and cell signalling79-80. S-
nitrosocysteine (SNOC) is less stable than GSNO, and little is known about it in 
comparison81. 
1.7. Overview of Wound Healing 
NO plays critical roles in the wound healing cascade. Wound healing begins immediately 
following insult or injury to tissues, persisting from several days to several months 
depending on the severity and location of the damaged tissue. The wound healing 
timeline (Figure 1.3) is composed of 5 stages: blood coagulation, inflammation, cell 
proliferation, lesion contraction, and remodeling19, 82. These stages do not proceed 
linearly; rather, instances of each overlap the preceding and following phases in a delicate 
balance. If interrupted or delayed, the wound healing process can be marginally extended 
or devolve into a chronic, non-healing state83. 
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Figure 1.3. Wound healing timeline. This figure shows the relative timeline of the wound healing 
process and its phases. 
Platelet adhesion and fibrin deposition begin the coagulation process in an attempt to 
stem the loss of blood, eventually forming a blood clot19, 82. Importantly, platelets will not 
adhere to healthy, normal endothelial cells, but will adhere to injured and exposed 
connective tissues through surface membrane adhesion receptors recognizing the amino 
acid sequence arginine-glycine-aspartic acid, commonly found in collagen82. Platelets 
will adhere to man-made materials, such as those typically employed in biomedical 
implants. At this point, the coagulation cascade, described above, is activated. 
Simultaneous growth factor secretion activates fibroblasts and endothelial cells, and 
beings macrophage recruitment to the affected area19, 82. 
The inflammation phase begins by recruiting neutrophils, lymphocytes, and macrophages 
to protect the exposed tissue. Additionally, macrophages begin removing the damaged 
tissue in preparation for tissue regeneration and scar formation19. The vasculature 
becomes leaky, and alterations the normal flow of blood may occur84. Granulation tissue, 
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defined by the numerous capillaries and red coloration, is indicative of a normal 
resolution of the inflammatory phase of the wound healing process19, 82. 
The proliferation phase of wound healing generally overlaps the inflammation phase and 
begins by encouraging angiogenesis at the wound site to develop the architecture required 
for continued remodeling and repair, often occurring approximately 3 days after the 
primary insult83. Growth factors, such as those released from activated platelets, attract 
neutrophils and monocytes from the flowing blood82. These initial growth factors are then 
degraded through protease reduction to be replaced by growth factors, such as vascular 
endothelial growth factor (VEGF) and fibroblast growth factor (FGF), produced by the 
recruited neutrophils, endothelial cells, macrophages, and fibroblasts. In addition, 
fibroblast migration and re-epithelialization occurs. This process can last up to several 
weeks19, 82. 
The lesion contraction phase is a dynamic, loosely condensed set of processes which 
prepares the wound site for the remodeling phase. Cells, especially fibroblasts, deposit 
extracellular matrix (ECM) proteins beginning at the wound margin proceeding inward. 
Transforming growth factor-β (TGF-β) stimulates fibroblasts to produce collagen, 
fibronectin, and glycosaminoglycans (GAGs), while platelet-derived growth factor 
(PDGF) encourages the production of fibronectin and hyaluronic acid. ECM deposition 
forms a provisional matrix allowing cellular migration, protein synthesis, and further 
support for angiogenesis. Concurrently, neovascularization continues through this stage 
to support the newly formed tissue. VEGF, released by both macrophages and endothelial 
cells, plays a critical role in the formation of angiogenic sprouts required to supply 
nutrients and oxygen to the rapidly forming tissue. Just prior to the remodeling phase, the 
granulation tissue developed throughout the inflammation and proliferation phases begins 
to retract and become a more densely packed, compacted structure. The mechanism 
behind this phenomenon is attributed to the contractile activity of myofibroblasts19, 82. 
The remodeling phase begins with tissue deposition in areas containing abundant 
collagen. During this phase, cells undergo apoptosis to form a relatively acellular scar, 
while growth factor migration subsides. Tissue remodeling during this stage results in 
changes to the collagen synthesis, where the ratios of the types of collagens and their 
structure and organization differ from normal, healthy tissue. The remodeling phase can 
last from weeks to several years19, 82. 
1.8. Nitric Oxide’s Role in Wound Repair 
NO’s presence and role in wound repair is demonstrated in every major step, from the 
mediation of inflammation to recruitment and control over macrophages, angiogenesis, 
platelet aggregation and clot formation, and finally matrix deposition and eventual tissue 
remodeling3, 19, 82, 85. During inflammation, reactive nitrogen and reactive oxygen species 
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are released by activated platelets and inflammatory cells, causing localized tissue 
damage, including damage to surrounding healthy cells5, 86. 
NO plays an important role in angiogenesis, which is a critical step in the wound healing 
process. Without neovascularization, nutrients, oxygen and waste are unable to be 
transported from the neo-tissue. Similarly to other physiological roles of NO, the level 
and duration of exposure is a large contributing factor to the pro-angiogenic or anti-
angiogenic response to NO5. NO can promote angiogenesis through inhibition of 
endogenous anti-angiogenic factors and has demonstrated an ability to recruit bone 
marrow-derived cells and perivascular cells during angiogenesis5. VEGF, shear stress, 
angiopoietins, and metabolic stress are potential factors causing endothelium-derived NO 
expression by eNOS5, 87.  
1.9. Nitric Oxide’s Role in the Immune Response & Inflammation 
During early research into immune function, NO was known to be a component in the 
function of activated macrophages. Since then, a significant number of NO’s roles in the 
immune response have been discovered. These include a broader understanding of its 
function in infection control, regulation of signaling cascades, transcription factors, 
leukocyte activity and cytokine production, as well as leukocyte proliferation and 
apoptosis13, 37, 88-89. Transcriptional regulation, such as that demonstrated in the nuclear 
factor kappa B (NF-κB)/Rel pathway5, 13, 90-92, by NO of cellular responses to nitrosative 
and oxidative stress is also a large component in the immune response13. 
NO has been shown to regulate the function of neutrophils, including the degranulation, 
superoxide generation, and chemotactic movement. It is also known as a regulator of 
recruitment13. Endogenous NO and NO donors have demonstrated regulation of 
leukocyte rolling and adhesion to injured endothelium, with a potential dependency on 
cGMP93-94. Globally, NO is known to down regulate leukocyte adhesion molecules such 
as E-selectin95, P-selectin96, and intracellular adhesion molecule-1 (ICAM-1)13, 94. 
NO also has roles in the regulation of immune function. As an immune regulator, NO is 
believed to function by regulating cell proliferation and death through the inhibition of 
specific genes34. As in other functions throughout the body, NO is also believed to 
possess anti-apoptotic effects. NO has been shown to regulate mast cell function, and 
when produced with IFN-ϒ, inhibits the immunoglobin based secretions of mast cells, to 
include histamines34. 
Conversely to these observations, NO has also demonstrated some capacity to inhibit 
factors and processes normally though to be beneficial in the immune response, including 
inhibition of cytokines produced by lymphocytes, monocytes, and eosinophils97-98. These 
cytokines include several classes of interleukins, IFN-ϒ, and TNF-α34, 99. 
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While an important part of the immune response, significant quantities of the superoxide 
anion generated in leukocytes can cause damage to healthy endothelium, resulting in 
vascular permeability and apoptosis34, 100. Recent evidence suggests that NO can 
contribute to the inflammation response through regulation of inflammation mediators 
through the production of intracellular ROSs. In particular, non-phagocytic oxidases 
(NOXs) can be constitutively released in several tissue types34, 101. ROSs produced by 
these enzymes have demonstrated control over adhesion molecule regulation as well as 
chemokine and cytokine expression102-103. Stimulation of MAP-kinase activity has been 
linked to these ROSs, activating transcription factors34. 
NO has several roles in both the acute and chronic inflammatory processes. In the acute 
stage of inflammation, NO production from eNOS induces vascular smooth muscle cell 
relaxation, ultimately leading to increased vascular permeability due to leaky endothelial 
cells. This response is, in part, responsible for the swelling and redness associated with 
the early stage inflammation response104. Septic shock is believed to originate from an 
overproduction of NO by iNOS in response to the bacterial infection, eliciting an acute, 
systemic inflammatory response104. Production of both peroxynitrite and superoxide are 
increased during inflammation13, which has been implicated in further damage to the 
surrounding medium. In addition, superoxide production may deplete NO reserves in the 
local environment. 
1.10. Nitric Oxide’s Role in Cellular Proliferation 
As in other aspects of NO’s functionality, its effect on cellular proliferation maintains a 
significant dependency on the level, duration and timing of NO exposure. NO is 
simultaneously capable of inhibiting cellular migration and inducing senescence, while 
also promoting cellular proliferation29, 105-107. In human umbilical vein and coronary 
artery endothelial cells, NO has been shown to inhibit their proliferation at concentrations 
above 100 μM108. Vascular smooth muscle cell (vSMC) proliferation is inhibited in a 
dose dependent manner by NO through cGMP dependent and independent mechanisms9, 
40. In contrast, NO is also known to cause cellular proliferation in cultures containing 
nanomolar concentrations of NO107, 109-110. Up regulation of VEGF stimulates NO 
production from eNOS, eliciting endothelial cell proliferation, migration, and 
organization to form angiogenic sprouts9, 111-113. 
NO also maintains some control over cellular apoptosis through the p53 tumor suppressor 
gene, B-cell lymphoma 2 (Bcl-2), and mitochondria114. High concentrations of 
extracellular NO induce apoptosis through the aforementioned inhibition of 
mitochondrial ATP production and direct oxidative and nitrosative damage of cellular 
membranes115. NO can regulate apoptosis through S-nitrosylation of NF-κB and Bcl-292, 
116. Alternatively, and of particular interest in anti-tumorigenic therapies, p53 can lead to 
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cellular apoptosis after oxidative DNA damage by NO5. NO can inhibit apoptosis through 
radical interferences and cGMP117-118. These effects have been observed in endothelial 
cells, vascular smooth muscle cells, and hepatocytes5, 119. 
1.11. Nitric Oxide’s Role in the Vascular System 
In addition to the previously mentioned effects of NO on the vascular system, laminar 
shear stress exerted on the endothelial arterial and venous lining maintains a propensity to 
elicit NO generation via eNOS production120. Shear stress increases up regulation of NO 
output from eNOS by acutely increasing the intracellular Ca2+ levels, leading to an 
increased prevalence of calmodulin binding to eNOS121. Though the initiation of shear 
induced NO generation seems to be due to intracellular Ca2+ levels, the production of NO 
during shear stress far exceeds the ability of Ca2+ alone120, 122. Intracellular calcium-
independent production of NO due to shear stress is a direct result of phosphorylation of 
sites on eNOS resulting in an electron flow from the reductase to the oxygenase 
domains120, 123-124. The most common of these in human eNOS are Ser1177 and Thr49542. 
After several hours of exposure to laminar shear stress, eNOS production is upregulated, 
permitting the production of higher NO concentrations120. 
Oscillatory shear stress, on the order of ±15 dynes·cm-2, also stimulates NO generation 
and eNOS synthesis through a similar pathway as in the laminar shear stress case. Unlike 
the pathway leading to an increase in NO production under laminar flow conditions, 
ROSs including superoxide and hydrogen peroxide are produced in the endothelial cells 
during oscillatory flow conditions and lead to the observed increase in NO through a 
separate, but related, mechanism as determined in the laminar shear state42, 120, 125-126. 
Under both laminar and oscillatory shear conditions, superoxide and hydrogen peroxide 
are produced by NADPH oxidase, albeit under different pathways42, 120, 127. 
Concomitantly, superoxide dismutase and glutathione peroxidase is produced to scavenge 
these components, respectively120, 128-129. 
1.12. Physiological Nitric Oxide Measurement Techniques 
NO measurement from biological sources is of the utmost importance in gaining an 
understanding of its seemingly endless roles within the body. When the task of in situ 
measurement is approached, researchers often encounter severe limitations in both access 
to the source and interference from other potential contaminants. Because it is a free 
radical and extremely labile molecule, NO readily reacts with molecular oxygen, 
ubiquitously present in the environment and physiology130. Coupled with its extremely 
short half-life, this makes the measurement of NO challenging. The relatively miniscule 
amounts of NO available also make its measurement a daunting task. Several techniques 
have been developed which allow researchers to determine the total amount of NO 
produced, however few offer the ability to detect, in real time, the generated NO flux. 
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Both types of information are required to make solid conclusions about the efficacy of 
NO as a therapeutic agent131. 
One of the earliest indirect measurement techniques applied to NO was a diazotization 
assay described by Peter Griess in 1879132-133. It is the most commonly used NO analysis 
technique today due its simplicity, cost, and robustness131. In this assay, the stable 
autoxidation product of NO, nitrite (NO2ˉ), is analyzed to estimate the amount of NO 
produced within a sample, and compared to a NaNO2ˉ or NaNO3ˉ standard curve36, 131, 134. 
The Griess reagents consist of sulfanilamide, HCl, and N-(1-napthyl)-ethylenediamine 
(NED)36, 63, 135. The reaction produces an azo dye that can be analyzed through an 
absorption measurement with a spectrophotometer at 458 nm63. As NO can be oxidized to 
nitrate (NO3ˉ), the sample must first be treated to reduce NO3ˉ to NO2ˉ 134. The Griess 
reagent assay can effectively detect nitrite in the range of 0.1–40 μmol/L with a 
sensitivity of approximately 1 μmol/L63, 131, 134.  
The most common downfalls reported with the Griess assay are the low detection limits 
compared to alternative methods and the necessity of eliminating contributions due to 
background NO2ˉ and NO3ˉ 131, 134. Additionally, Griess reagent detection of NO is 
unable to be used for real-time analysis of NO production due to the necessary detection 
methods and chemical reactions131. 
Direct amperometric measurements by electroxidation of NO with platinum, carbon, or 
polymeric porphyrin electrodes are possible due to the oxidation reaction at the 
electrode’s tip36, 63, 134-135. A three electron transfer from NO to the grounded anode 
generates NO+ which is further converted to nitrite (NO2ˉ) in the presence of OHˉ 
(Equations 13.1–13.3)36, 63, 134. The current generated in the oxidation reaction is directly 
proportional to the concentration of NO. This technique provides favorable results with a 
linear response over small concentration ranges, with reported nanomolar (10 nmol/L) 
sensitivity130, 134. To date, detection limits as low as 83 pM and dynamic linear ranges of 
0.2 nM–4.0 μM have been reported63, 131, 136. The high sensitivity and response times 
make this measurement technique favorable for in situ analysis of NO kinetics36. 
Trapping of NO under the probe tip can lead to artificially elevated NO levels. In these 
cases, microelectrodes with tip sizes ranging from 30–200 μm can be used to minimize 
this effect134. Small probe sizes allow NO measurements to be taken from single cells63. 
  (13.1) 
 
 
(13.2) 
 
 
(13.3) 
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An incredibly versatile, direct measurement assay is the chemiluminescent analysis of 
NO. Developed initially to detect NO in smog130, this technique has been adopted both in 
the physiological measurement of NO in research, but also in clinical settings from 
exhaled breath. In a reaction with ozone, NO generates an excited state radical NO2 and 
molecular oxygen36, 63, 131, 134, 137. As the radical relaxes and returns back to its ground 
state, it emits photons whose wavelengths vary between 640–3000 nm with a peak in 
intensity seen at 1100 nm3, 135. The reaction is shown in equations 14.1–14.2. This 
technique is often coupled with a photomultiplier tube (PMT) to detect gaseous NO 
above the headspace of a liquid or solid sample, and the generated PMT signal is directly 
proportional to the NO levels, and is thus linear36, 63, 131, 135. The PMT itself is capable of 
detecting wavelengths between 600–900 nm63, 130-131, 134, 138. Though this reduces the 
detection limit, it is still sufficient for chemiluminescence to be the most sensitive NO 
detection method currently available3. A reduction in the reaction chamber pressure 
sharply decreases the number of potential molecules that could quench the signal3. 
  (14.1) 
 
 
(14.2) 
 
The rate of reaction between NO and O3 is approximately 107 L·mol-1·s-1, while the 
sensitivity of NO2* detection of light emitted from the reaction is 100 pmol/L134. These 
reaction rates, coupled with PMT based detection, offers real-time NO measurement, 
allowing significant insight into the reaction kinetics of NO generation63. The gaseous 
NO is transported to the reaction cell under vacuum in combination with an inert 
sweeping gas (often nitrogen) to prevent reaction with O2. The specificity of the assay 
technique is very high, where only NO and one other component may be detected. H2S 
will react with ozone in the same manner as NO, however the emission wavelength 
generated will be of a different wavelength, easily removed from the signal by a red band 
pass filter36, 130-131, 134. In addition, gas phase measurement ensures that nitrites, nitrates, 
and other common biological components that would otherwise react with O3 are 
excluded130. The response time of the measurement is dependent on the concentration of 
NO and the integration time of the PMT. The sensitivity of chemiluminescent detection is 
commonly reported between 20–50 pmol130. The dynamic range of the instrument is 
exceptionally large, with detectable limits between 0.5 ppb (0.66 pM in 100 mL PBS) to 
500 ppm63, 131. 
Often, groups investigating the behavior and applications of NO report its presence in 
concentrations. This method is useful in the chemical analysis of NO, however it can be 
misleading when reported in therapeutic applications. Many groups have found that 
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reporting NO values as a flux delivered over an area to be a better assessment of the true 
dose received by the target. The discrepancies between the reporting methods and 
subsequent difficulty in comparing values and doses between groups has become a 
significant hurdle as NO becomes a more desirable therapeutic agent. Often, key 
information including the flux, duration and rate of release, and method of delivery are 
not given in published research. Additionally, the mass, volume, or porosity of the 
sample is required to normalize the data to other published results. To truly assess the 
efficacy of NO as a therapeutic agent, this information is required for an accurate 
comparison131. 
The predicted concentration of NO in physiological environments is estimated between 1 
nM and 100 nM, while other methods predict significantly lower values of 100 pM–5 
nM11, 139-142. On activation of macrophages during illness, injury, or inflammation, these 
levels will increase by several orders of magnitude. Though many groups utilize 
concentration based measurements of NO, others have found that a measurement of NO’s 
basal flux is a more accurate method of determining NO dosage in therapeutic 
applications. The currently accepted estimate for the endogenous NO flux generated from 
an intact, healthy endothelium is 0.5–4×10-10 mols·cm-2·sec-1 143-144. 
1.13. Classes of Nitric Oxide Donors 
Several classes of NO donors, including S-nitrosothiols, N-diazeniumdiolates, 
nitrosamines, metal nitrosyl complexes, and nitrates have been developed, however 
translation to clinical use has been lacking in their continued development19, 145. In order 
to attain clinical relevancy, NO donors must be able to deliver specific, easily definable 
therapeutic levels of NO. Here, N-diazeniumdiolates and S-nitrosothiols will be explored. 
N-diazeniumdiolates (NONOates; X-[ˉN(O)=ONˉ]) were first synthesized in 1960 by 
Drago and Pualuk by combining diethylamine and NO146. N-diazeniumdiolates are 
formed through a reaction between two moles of NO and materials containing primary or 
secondary amines under high pressure, creating a relatively stable donor capable of 
releasing NO from 2 seconds to 17 days147-151. Two moles of NO can be generated from 
one mole of compound149-150. As this results in a negative charge being imparted on the 
N-diazeniumdiolate, a counteraction (Na+) must be present. A zwitterionic compound can 
be formed to stabilize the N-diazeniumdiolate by protonating another amine on the same 
molecule147, 152. 
N-diazeniumdiolates are often used for the spontaneous generation of NO, either in 
aqueous solutions or as device coatings148. The decomposition rate is dependent on the 
structure of the nucleophile146. The decomposition of N-diazeniumdiolates proceeds 
through first-order kinetics, independent of biological mediators and catalysis by thiols, 
and thus their decomposition rate is predictable146. The spontaneous decomposition of N-
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diazeniumdiolates under physiological conditions offers an easy method of delivery with 
a wide range of applications149. N-diazeniumdiolates are often tailored to a specific 
application through alterations of the pH, amine structure of the precursor, and the 
temperature148. Many groups have successfully incorporated N-diazeniumdiolates into 
polymers through covalent attachment for use in implantable devices151, 153-156. After 
some clinical use, N-diazeniumdiolate administration for patients with ischemic heart 
disease was discontinued after some evidence of tolerance to the organic nitrates was 
observed157.  
S-nitrosothiols have been shown to decompose through several mechanisms: S–N bond 
homolysis, transition metal ion catalyzed decomposition, photolytic S–N bond cleavage, 
direct interactions with ascorbate, and hydrolysis12, 151, 158. Homolytic decomposition of 
an RSNO generates NO and an alkyl thiyl radical (RS•) (Equation 15.1), while 
heterolytic decomposition produces either NO- or NO+ and a corresponding RS+ or RSˉ 
(Equation 15.2)10, 53, 64, 159. Generally, both mechanisms are involved in the 
decomposition of NO. Homolytic decomposition generally occurs through thermal or 
photolytic pathways and is slow in the absence of these contributors53. 
 
 
(15.1) 
 
 
(15.2) 
 
Transition metal cleavage requires a transition metal, such as Cu2+, to be reduced to Cu+. 
Cu+ reacts with the nitrosothiol to generate NO forming sulfhydryl (-SH) and 
regenerating Cu2+ (Equations 16.1–16.2)147. Photolytic cleavage of an RSNO evolves NO 
and a disulfide compound formed from the parent thiols145. In the formation of S-
nitrosothiols, it is generally accepted that a nitrosothiol is not produced via the direct 
reaction of NO and thiol. Rather, a mechanism incorporating molecular oxygen has been 
proposed160. 
  (16.1) 
  (16.2) 
 
Release of NO from SNAP by photolytic cleavage is most efficient at wavelengths 
corresponding to its S-nitroso absorption bands (330–350 nm and 550–600 nm) 
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(Equation 17)161. The molar absorptivity of SNAP is reported as ε340=1075 M-1·cm-1 and 
ε590=12.4 M-1·cm-1 162-163. 
 
 
(17) 
 
Generally, tertiary S-nitrosothiols appear green, whereas primary or secondary S-
nitrosothiols appear red159. UV/Vis spectrophotographic measurements of S-nitrosothiols 
show absorption peaks between 225–261 (ππ*), 330–350 (n0π*), and 550–600 
(nNπ*) nm50, 159. Tertiary RSNOs shows two distinct absorbance maxima at 340 nm 
(π→π*) and 590 nm (nN→π*) with a broad shoulder extending towards 550 nm, 
providing a simple method for positive identification of tertiary RSNO formation53, 163. 
When analyzed together, these peaks allow a reaction’s progress, successful formation of 
the RSNO, and eventual decay to be monitored50, 163-164. Typically, the least energetic 
bands are used to monitor the progress of reactions involving S-nitrosothiols. 
S-nitrosothiol stability is dependent on the substituent organic structure, as evidenced by 
the relative instability of primary RSNOs as compared to the long-term stability of 
tertiary RSNOs165. S-nitrosothiols, such as S-nitroso-N-acetyl-D-penicillamine (SNAP), 
generally exhibit –SNO moieties with an anti-orientation almost exclusively165. This 
RSNO is thought to exhibit extended stability over NO alone; due, in part, to the 
production of the free radical NO at the point of use161. SNAP is a well-known and 
extensively studied biocompatible NO donor which maintains excellent stability in the 
physiological environment19, 53, 64, 78, 163, 166.  
Some groups consider S-nitrosothiols to be donors of NO+ through heterolytic cleavage 
of the SN bond, allowing easy transfer across the plasma membrane53, 146. This form of 
release is attributable to trans-nitrosation, and would allow additional thiols to pass on the 
biological activity without the release of free NO, making deleterious side reactions less 
likely while protecting NO from side reactions with oxygen species146. Dimerization of 
the thiyl radical forms a disulfide (RSSR) (Equation 18)64, 159. 
  (18) 
 
In an implanted system, overproduction or excessive delivery of NO is circumvented 
through the implementation of controlled release mechanisms. In the event that these fail, 
the physiological reactions described above will convert the free NO to less harmful 
compounds to reduce the potential harmful effects of NO on surrounding tissue. Since the 
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effects of NO are diffusion and degradation rate limited, the extent of any damage would 
be localized to within NO’s radius of activity of 100 μm31, 64-66. 
1.14. Medical Applications of Nitric Oxide Donors 
Due to NO’s pervasive nature in the physiological environment and myriad of functions, 
synthetic delivery of NO via donors can be valuable both in the basic biological 
understanding of NO, but also as a clinically relevant, therapeutic agent. 
As research tools, well characterized and understood NO donors can provide effective 
methods to replicate and verify theories and models about NO’s effect on the 
physiological environment. Dose dependencies and basal release of NO from cells can be 
determined167. In addition to their potential as research tools, NO donors have found a 
well-deserved place in medical research and clinical practice. First used medicinally in 
1849 in the form of nitroglycerine, NO donors have been in successful clinical use for 
over 150 years1. Over the past several decades, once the connection between EDRF and 
NO was discovered168, the breadth of knowledge pertaining to improved delivery and 
storage mechanisms of NO has led to remarkable gains in the field of drug delivery30, 147, 
169-170, vascular substitutes8, 19, 153, 171-172, cancer treatments29, 173-176, respiratory 
illnesses177-180, and neural regeneration181-183. Additionally, NO is now able to be used in 
the diagnosis of certain clinical pathologies184-192. 
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Chapter 2: Introduction to Small Diameter Vascular Grafts 
 
2.1 The Arterial Structure 
Arteries are composed of a concentric, layered structure which endows them with the 
ability to respond to physiological and chemical cues to alter their physical structure. The 
arterial structure can be subdivided into three major, histologically distinct, components: 
the intima, the media, and the adventitia1. Further subdivisions can be made and are 
shown in Figure 2.1. 
 
 
 
Figure 2.1. The structure of an artery. Figure 2.1 shows the typical organization of the tissue in the 
arterial wall. Reprinted with permission from John Wiley & Sons1. 
The intima, which forms the lumen of the vessel, is composed of a monolayer of vascular 
endothelial cells (vEC) connected to a basement membrane composed of collagen IV and 
laminin2. The vEC’s functions include regulation of angiogenesis, the creation and 
maintenance of a selective barrier, and the formation of a non-thrombogenic blood 
contacting layer2-3. While the vEC monolayer presents a non-thrombogenic surface to the 
blood, the basement membrane presents a highly thrombogenic surface. Thus, when 
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damage occurs to the endothelium, platelets will adhere to the exposed underlying 
basement membrane. In a case where more extensive damage has occurred, the highly 
thrombogenic collagen of the sub-endothelial connective tissue will promote platelet 
attachment to the exposed surface, instigating a thrombotic response1. The fenestrated 
internal elastic lamina covers the basement membrane2. 
The medial layer, composed largely of collagens I and III, consists of a layer of vSMCs 
bounded by an internal and external elastic lamina1-2. The vSMC layer has a 
circumferential orientation along the central axis of the vessel. Due to their arrangement, 
the coordinated contraction or relaxation of vSMCs results in the regulation of vascular 
tone and diameter through a response to cues from circulating cytokines and endothelial 
cells2. The external elastic lamina separates the medial layer from the collagen containing 
adventitia2. 
The adventitial layer is mainly composed of connective tissues, including collagen and 
embedded fibroblasts1. These components contribute to the mechanical strength of the 
artery while promoting integration with the surrounding environment. On the adventitial 
surface, collagen acts as a substrate for the vasa vasorum1. 
Native arterial mechanical properties have been found to be anisotropic in nature, 
endowing arterial vessels with high elasticity under low pressure conditions while 
maintaining low distensibility and increased stiffness at high pressures4. The laminar and 
circumferential arrangement of collagen and elastin fibers confers these properties to 
arterial vessels4. Studies have demonstrated that elastin fibers are active elements under 
pressure until approximately 120 mmHg, after which the stress is transferred fully to 
collagen fibrils4. 
2.2. The Current Status of Small Diameter Vascular Grafts 
To date, few viable options exist in the treatment of pathologies involving small diameter 
arteries (< 6 mm), though the saphenous vein, internal mammary artery (IMA), the 
umbilical cord artery, and radial artery are all viable options5-7. The saphenous vein is the 
current standard for coronary artery bypass grafts (CABGs) (Figure 2.2). However, 
complications, previous surgeries, and pre-existing pathologies can render that route of 
treatment inappropriate for approximately 5–33% of the patient population6-8. Autologous 
arteries and veins used as vascular grafts account for approximately 500,000 procedures 
each year and are the gold standard in vascular interventions9-10. Currently, no engineered 
construct is capable of reliably replacing autologous vascular substitutes. 
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Figure 2.2. Coronary artery bypass graft. Figure 2.2 shows the common donor sites and vessels 
used in coronary artery bypass grafts. Reprinted with permission from Encyclopaedia Britannica11.  
Several decades ago, the standard for large diameter vascular grafts, expanded 
polytetrafluoroethylene (ePTFE), was evaluated for use in small diameter applications6, 
12. In contrast to the outcomes observed in large diameter trials, small diameter grafts 
fabricated from ePTFE showed significant thrombosis, neointimal hyperplasia, and 
restenosis3, 13-18. Poly(ethylene terephthalate) (Dacron) has also been evaluated for use in 
small diameter vascular grafts5, 19-20. The outcome was similar to that of ePTFE. 
In short term trials, these synthetic grafts perform favorably, however late term 
performance decreases rapidly, often attributed to poor luminal biocompatibility, low 
flows, and compliance mismatches, resulting in a chronic thrombogenesis, anastomotic 
intimal hyperplasia, and late stage failure from neointimal hyperplasia5-6, 21-23. Synthetic 
grafts demonstrate suboptimal patency rates of 30% after 5 years24. Both natural and 
synthetic small diameter vascular grafts have been under development, reporting varied 
degrees of success and patency6, 8, 12. 
In contrast, the saphenous vein grafts are significantly improved over synthetic grafts, 
with patency rates of 75% over 5 years24. However, the best available vascular graft for 
CABGs, to date, is the human internal mammary artery (IMA). The IMA demonstrates a 
95.8% patency rate as compared to 75–82.4% patency rate for the saphenous vein after 5 
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years5, 25. Additionally, atherosclerosis is rare in the IMA, and speculations abound of its 
high elastin content being a significant contributing factor to its substantial patency rate5, 
26-27. In spite of its successes, the IMA has its own complications, as the extensive surgery 
required during a bilateral IMA harvest can lead to an increased prevalence of 
complications during wound healing and donor site morbidity5, 28. Each of the vascular 
grafts presented above have been previously evaluated. However, a trend of increased 
patency rates with increasing elastin content, a seemingly key contributing factor to the 
graft’s performance, might have been overlooked. 
An ideal vascular graft would possess a native architecture closely mimicking the 
properties of the substituted vessel, maintain a blood contacting surface that was both 
non-thrombogenic and non-immunogenic, and originate from a readily available, easily 
replenished source. Shelf stability over extended time periods would make the vascular 
graft more adaptable to each individual patient and expedite the transition to clinical 
adoption. 
2.3. Mechanisms of Small Diameter Vascular Graft Failure 
Thrombosis is often the dominant failure mode during early stage (< 1 month) post-
surgical recovery following surgical interventions utilizing small diameter vascular 
grafts28. Formation can occur either at the injury site or distally along the length of the 
vessel. Often, the underlying causes of the thrombotic response are attributed to the 
denudation of the endothelium or partial disruption of the endothelial monolayer, graft 
ischemia, and turbulent flow at the anastomoses due to a size or compliance mismatch28. 
Intimal or neointimal hyperplasia is an exaggerated healing process that occurs following 
injury to the vascular wall7, 29. Neointimal hyperplasia is generally initiated by injury to 
the vascular wall resulting in denudation of the endothelium, exposing the thrombogenic 
basement membrane and vSMCs to circulating blood29. Restenosis, or a reoccurrence of 
vascular stenosis, is often attributed to neointimal hyperplasia and is defined as a 
reduction in a vessel’s luminal diameter of more than 50%30-31.  
Within seconds post-injury, the cascade towards intimal/neointimal hyperplasia first 
begins with platelet aggregation and adhesion to the underlying tissue, followed closely 
by fibrin deposition and thrombus formation31. Following platelet attachment, leukocyte 
chemotaxis and vSMC proliferation occur at the site of injury29, 31. Migration of vSMCs 
due to basic fibroblast growth factor (bFGF) exposure then occurs, followed by 
endothelial cell proliferation due to activated platelet derived factors29, 31. As vSMCs 
undergo a transition from the contractile state to the synthetic state, they migrate into the 
intimal layer and begin proliferating31. Under normal physiological conditions, the elastic 
laminae prevent vSMC migration into the intimal layer. Post-injury, ECM remodeling 
and collagen deposition allows cells to penetrate this barrier, forming the neointima29, 31. 
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Onset of intimal hyperplasia often develops prior to thrombosis, and is considered a 
medium to long term event1. It is thought that the elastic mismatch between current grafts 
and the native architecture contributes to intimal hyperplasia, attributable to the resultant 
turbulent flow and shear stress4, 23. 
2.4. Classes of Small Diameter Vascular Grafts 
Current research in the field of small diameter vascular graft fabrication has revealed 
several promising approaches to address some of the deficiencies in available 
technologies. Tissue engineered vascular grafts (TEVGs), decellularized constructs, 
electrospun vessels, and drug eluting polymeric vascular grafts are all under 
development. 
One of the more prevalent techniques under development centers on the use of TEVGs. 
Three elements are required for TEVGs to work, deemed the tissue engineering triad: a 
biodegradable scaffold to promote neo-tissue formation, cells, and the signals required to 
promote differentiation and proper function17, 32. In this approach, an extracellular matrix 
based scaffold is fabricated with the intention of seeding and then culturing the patient’s 
matching cells within the structure. A variation on this technique which has also shown 
some promise is the use of rolled cell sheets to form a tubular vessel12, 33. After a period 
of time, the graft becomes re-endothelialized and the specific cell types regain their 
original functions with the addition of humoral and mechanical signals imparted during 
fabrication. Re-endothelialization allows the vascular substitute to prevent post-
implantation thrombosis through regulation of platelet adhesion1. 
As in native tissue, the structure and function of the vascular graft will be dependent on 
the organization and function of the individual components. Endothelial cells must re-
endothelialize the lumen of the TEVG and remain attached, a critical aspect of 
thromboresistance and the prevention of neointimal formation through the suppression of 
smooth muscle cell proliferative factors and stimuli17. While the importance of a 
confluent monolayer is undisputed, fibroblasts and smooth muscle cells are critical to the 
formation and proper function of a TEVG17. Studies by Weinberg and Bell as well as 
Noishiki et al. revealed that graft seeding, regardless of cell type, accelerated 
endothelialization17, 34. Many groups are actively investigating the use of stem cells, 
where the ultimate goal of natural cellular differentiation based upon the local 
environment could create a universal source of cells33. 
In the physiological environment, oxygen maintains a diffusion limit of 200 μm3. Thus, 
capillaries originating from the vasculature are required to supply oxygen and nutrients to 
surrounding tissue. Much like other organs and tissues, the vessels themselves must have 
a supply of oxygen and nutrients and rely on a network of vessels known as the vasa 
vasorum. The development of this support system has become a significant hurdle in the 
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development of cell sheet and tissue engineered vessels. Waste generated in the cells, 
such as CO2, are also removed by the capillaries3. Some groups have developed methods 
of inducing angiogenesis in cell sheet and TEVG based synthetic grafts in an attempt to 
pre-vascularize the construct and optimize the growth and formation of the vessel during 
bioreactor perfusion. Eventually, these neo-vessels will connect to the patient’s existing 
vasculature3. This can be accomplished through pre-vascularization of an in vitro 
construct, whereby a rudimentary vasculature is built into the underlying structure, or 
through the administration of angiogenic cytokines during in vitro culture3.  
A significant advantage in the use of stem cells comes from their ability to self-
regenerate. In culture, biological and mechanical signals are required to begin cellular 
differentiation. In the absence of these signals, the cells would exist in a latent state. 
Induction of cellular differentiation could be initiated prior to implantation, allowing for 
excellent temporal control of the graft development17. While the theory behind this 
approach is solid and appears promising, the time required for fabrication of the grafts 
and their relatively delicate handling properties have shown limited in vivo and clinical 
successes. 
Allogenic and xenogenic decellularized constructs are being investigated as scaffolds in 
the development of vascular grafts due to the ability to retain the native ECM architecture 
while providing preferential reorganizational capacity for a patient’s native cells6, 17. The 
advantage of decellularized constructs over cell-synthesized, tissue engineered substrates 
comes from the natural, rather than cell-stimulated, organizational structure of the ECM. 
This structure can be retained through non-destructive processes such as protein or ECM 
digestion and decellularization. Additionally, decellularization removes any potential 
antigenic material which may provoke a stress immune response though the application 
of physical agitation, chemical digestion, surfactant washes, and enzymatic digestion17. 
Severe processing of decellularized scaffolds required to remove all of the antigenic 
material may cause excessive damage to the ECM components. Unfortunately, improving 
the mechanical properties of decellularized materials becomes more challenging than 
other tissue engineering approaches17. One of the significant criticisms of the 
decellularized constructs is the inherent lack of a suitable, non-thrombogenic, blood 
contacting surface12. Native elastin has been proposed as a potential solution to this 
deficiency35-36. 
Electrospinning was originally introduced in the 1930s as a novel method of textile 
manufacturing28. It has recently been adopted to fabricate nanoscale polymer fibers for 
medical use. Electrospinning provides an economical, rapid method to fabricate tubular 
constructs with minimal processing time that allows almost infinite tuning of the 
material, mechanical, and topographic properties of the finalized construct. 
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A basic electrospinning apparatus requires four components: a voltage supply, a 
grounded collector, a dissolved polymer solution, and a delivery mechanism (Figure 2.3). 
A typical electrospinner will have several additional components to control the alignment 
and distribution of the electrospun fibers. Generally, a polymer dissolved in an organic 
solvent is fed through a charged metal tube. This tube is elevated to a high potential, and 
placed over a grounded, static collector, generating an external electric field and 
imparting a charge imbalance to the system28. This charge imbalance results in the 
formation of a conical Taylor cone. As the charge imbalance of the electric field exceeds 
the surface tension of the polymer solution, a polymer jet is ejected from the opening of 
the tube. During the time required to reach the target, the solvent evaporates, forming a 
fibrous polymer mesh with no trend towards any specific fiber orientation. By rotating 
the collector, tubular constructs and aligned fibers can be formed28. 
 
Figure 2.3. A diagram of a basic electrospinner. A typical electrospinner is shown in Figure 2.2, 
comprising of a syringe pump, high voltage power supply, polymer solution, and rotating collector. 
Control over the electrospinning process requires careful consideration of many factors: 
the relative humidity of the electrospinning environment, the selected polymer and solvent, 
angular velocity of the collector, the accelerating voltage, and the length of the air gap. 
This is only a brief list of the elements that control the final product generated during 
electrospinning. 
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Electrospun fibers offer exceptional control over the material, mechanical properties, and 
morphology of a fabricated construct17. With fiber diameters ranging from the nanoscale 
to microscale, the mechanical properties of a vascular graft could conceivably be 
infinitely altered through materials selection, fiber morphology, fiber density, and fiber 
diameter. Due to the scale of the fibers, fabrication of nanotextured surfaces and the 
incorporation of mechano-chemical cues through electrospinning is possible17. The 
porosity of the fabricated construct can be tailored to match the application, and 
degradation properties of biodegradable scaffolds can be easily altered37. As many ECM 
proteins are deposited in fibrillar structures, it is possible for electrospun scaffolds to 
approximate this morphology to better mimic the native environment38. In fact, many 
groups have begun to electrospun native and synthetic ECM based materials in an 
attempt to replicate the native physiological architecture while maintaining some degree 
of control over the morphology and final chemical characteristics39-44. Anisotropic 
scaffolds can be fabricated through the use of aligned fibers, and aligned fibers have been 
shown to enhance endothelial cell migration45-46.  
Drug eluting grafts represent a directed approach to solving some of the many issues 
observed in small diameter vascular constructs. By incorporating one or more drugs into 
a construct, whether chemically or by mixing, several failings of current grafts may be 
addressed. Many groups have incorporated anti-thrombotic agents into polymeric 
constructs28, 47-49, while others have incorporated anti-proliferative agents to reduce or 
prevent neointimal hyperplasia50-52. Incorporation of the drugs into polymer substrates 
has resulted in the fabrication of electrospun, drug eluting vascular grafts28. Localization 
of a drug within a construct would promote directed delivery, while tailored release rates, 
durations, and levels, would substantially increase its efficacy28.  
The fabrication time of any vascular substitute is critical in its evolution as a clinically 
viable solution. Typical fabrication times of electrospun scaffolds vary between 10 
minutes to several hours, while TEVGs and cell sheet engineered products might require 
weeks to months33, 53-59. Eventually, a combination of electrospinning, 3D printing 
technology, and 3D imaging could be a promising approach for boutique, made while 
you wait, vascular grafts. Though graft fabrication time is important, storage stability and 
transport concerns are also a critical aspect in the fabrication of clinically viable vascular 
grafts. Incorporating materials which are easily stored and transported will lead to more 
rapid clinical acceptance than constructs with a finite lifespan.  
2.5. Elastin as a Blood Contacting Surface 
Elastin, a 67 kDa extracellular matrix protein, has previously demonstrated favorable 
properties as a blood contacting layer in small diameter vascular grafts60. Possessing 
biological properties such as low thrombogenicity, smooth muscle cell inhibitory 
42 
 
properties, and an endothelial cell favored surface, elastin is an ideal blood contacting 
layer in a small diameter vascular graft5, 61. However, native elastin is extremely insoluble 
and hydrophobic, leading to significant hurdles in its processing62. Synthetic elastin in the 
form of tropoelastin and synthetically produced elastin is cost prohibitive and its 
synthesis requires significant amounts of time63-66. Decellularization of native materials 
will maintain the chemical and mechanical architecture of the host tissue, improving the 
cellular integration and remodeling response, in vivo24. Due to elastin’s favorable 
properties in vascular grafts, many groups have attempted to incorporate elastin into 
hybrid and synthetic constructs22, 24, 60-61, 63, 65-66. Figure 2.4 shows the location of the 
elastin containing elastic lamina within the arterial structure. 
 
Figure 2.4. Elastin’s location and structure within the artery. (A) denotes the location of the elastic 
lamina within the arterial structure. (B) shows the typical distribution of the elastic lamina in a 
muscular artery (left) and an elastic artery (right). Reprinted with permission from Oxford University 
Press67. 
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Based on published research, native elastin provides an anti-thrombogenic and neointimal 
hyperplasia resistant blood contacting surface35-36, 60, 68. Thus, the quantity, organization, 
and location of native elastin within a vascular graft may have substantial effects on its 
performance.  
The human saphenous vein is currently the most common graft utilized for CABG 
procedures. Collagen content of the saphenous vein is 65%, which is significantly higher 
than in arteries69. The presence of significant quantities of collagen will elicit improved 
mechanical properties, however may also contribute to thrombogenesis and neointimal 
hyperplasia. The human umbilical cord artery, in stark contrast to the saphenous vein and 
IMA, possesses a negligible quantity of elastin. However, its branch free length of 50 cm 
and a readily available supply of new tissue makes the umbilical cord artery desirable for 
vascular grafts fabrication70.  
In contrast, the human IMA contains between 25–40% collagen, while elastin accounts 
for the majority of the remaining tissue69. The IMA is most like the vessel show in the 
right side of Figure 2.4B. The high patency rate of the IMA makes it an ideal vascular 
graft, however the extensive surgical procedures and delicate properties of the vessel 
have hampered its acceptance as a widespread substitute. When the patency data is 
considered alongside the elastin content of each respective type of vessel, the IMA 
becomes a strong contender in the search for an ideal vascular substitute. A hybrid 
vascular construct utilizing native elastin may be superior to current approaches and 
address some of the key criteria of an ideal vascular graft presented earlier. Overcoming 
the difficulties and shortcomings of native elastin may prove fruitful in the search for a 
clinically viable small diameter vascular graft.  
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Chapter 3: Overview of Project 
 
Chapters 1 & 2 provided the necessary background information for the following 
chapters. These chapters provide a foundation for the fabrication of a hybrid, three 
component small diameter vascular graft which will significantly reduce thrombosis, 
inflammation, and late stage neointimal hyperplasia that commonly plagues current small 
diameter vascular grafts. This product is envisioned as follows. 
The elastic lamina has been shown to reduce luminal thrombosis and migration of 
vSMCs, making it an ideal blood contacting material. Preservation of the native 
architecture through decellularization and decollagenization offers a viable process in the 
fabrication of small diameter, neointimal hyperplasia resistant vascular grafts. Combined 
with biostable or biodegradable polymeric coatings, the mechanical properties of the 
naturally weak elastic lamina can be sufficiently enhanced to create a viable vascular 
graft with good interfacial adhesion between layers. The development of this vascular 
graft is described in chapter 4. 
NO, already known to act against the effects of thrombosis and neointimal hyperplasia, is 
readily incorporated into polymeric films and fibers. Current literature reports many S-
nitrosothiols capable of controlled release of NO over periods of days to weeks. In 
clinical applications, NO release would ideally be extended over a time period of several 
months, during which time, a natural monolayer of endothelial cells can be deposited to 
restore the native vascular architecture. The NO donor described in chapter 5, SNAP-
cyclam, has demonstrated long term stability and release of NO at physiologically 
relevant levels. As a component in the finalized hybrid graft, this material will be 
incorporated in the medial and adventitial layers. 
To overcome the difficulty of controlled NO release in vivo, a novel method to generate 
NO was investigated. Transition metals are well known mediators of NO release from S-
nitrosothiols, the most common of which are copper and iron. Chapter 6 presents results 
suggesting that Co2+, Ni2+, and Zn2+ also cause RSNO decomposition and release NO 
from SNAP. Recent developments of zinc based biomaterials and its physiological 
presence make zinc a favorable material for in vivo applications.  
The envisioned graft will be a hybrid construct of the elements presented in chapters 4–6. 
Based on the structure of the artery shown in (Figure 2.1), the new graft will consist of a 
decellularized and partially decollagenized elastin blood contacting layer (intima). The 
media will be composed of alternating SNAP-cyclam doped polyether urethane 
electrospun fibers and zinc doped electrospun fibers. The adventitia of the proposed 
vascular graft would be composed of polyether urethane electrospun fibers. 
1The material contained in this chapter has been previously published. Reprinted with permission from 
McCarthy, C. W.; Ahrens, D. C.; Joda, D.; Curtis, T. E.; Bowen, P. K.; Guillory, R. J.; Liu, S. Q.; Zhao, F.; 
Frost, M. C.; Goldman, J. Fabrication and Short-Term in Vivo Performance of a Natural Elastic Lamina–
Polymeric Hybrid Vascular Graft. ACS Appl. Mater. Interfaces 2015, 7 (30), 16202-16212. DOI: 
10.1021/acsami.5b03892. Copyright 2015 American Chemical Society. 
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Chapter 4: Fabrication and Short-Term In Vivo Performance of a Natural 
Elastic Lamina - Polymeric Hybrid Vascular Graft1 
 
4.1. Abstract 
Although significant advances have been made in the development of artificial vascular 
grafts, small diameter grafts still suffer from excessive platelet activation, thrombus 
formation, smooth muscle cell intimal hyperplasia, and high occurrences of restenosis. 
Recent discoveries demonstrating the excellent blood contacting properties of the natural 
elastic lamina have raised the possibility that an acellular elastic lamina could effectively 
serve as a patent blood contacting surface in engineered vascular grafts. However, the 
elastic lamina alone lacks the requisite mechanical properties to function as a viable 
vascular graft.  
Here, we have screened a wide range of biodegradable and biostable medical grade 
polymers for their ability to adhere to the outer surface of the elastic lamina and allow 
cellular repopulation following engraftment in the rat abdominal aorta. We demonstrate a 
novel method for the fabrication of elastic lamina – polymeric hybrid small diameter 
vascular grafts and identify polyether urethane (PEU 1074A) as ideal for this purpose. In 
vivo results demonstrate graft patency over 21 days, with low thrombus formation, mild 
inflammation, and the general absence of smooth muscle cell hyperplasia on the graft’s 
luminal surface.  
The results provide a new direction for developing small diameter vascular grafts that are 
mass-producible and shelf stable; universally compatible due to a lack of immune 
response; and inhibit the in-graft restenosis response that is common to non-autologous 
materials. 
4.2. Introduction 
Small diameter blood vessels are required during coronary artery bypass grafting 
(CABG) to circumvent occluded coronary arteries. Currently, autologous arteries and 
veins used as grafts for the approximately 500,000 CABG procedures performed in the 
United States each year1-2 represent the gold standard. However, a significant number of 
patients (~33%) are not able to make use of autologous vessels due to preexisting 
conditions3. Presently, there is no engineered vascular graft that is reliably able to replace 
autologous blood vessels in application. 
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Both synthetic and natural vascular graft materials have been in use for several decades in 
large diameter arteries2-4. Synthetic examples include polymeric grafts fabricated from 
polytetrafluoroethylene (PTFE/ePTFE), poly(ethylene terephthalate) (Dacron), and 
polyurethanes4-5. However, small diameter synthetic vascular grafts are susceptible to 
high rates of failure due to thrombosis, intimal hyperplasia, and restenosis6-12. Natural, 
tissue engineered blood vessels (TEBVs) are under development and have achieved some 
clinical success1, 13. However, their expense, long fabrication time, short shelf life, and 
arduous regulatory pathway are expected to hinder their widespread clinical acceptance. 
Thus, there is a pressing need for small diameter vascular substitutes that can be mass-
produced, are shelf stable over long time periods, and do not provoke excessive 
thrombosis or neointimal hyperplasia. 
Decellularized elastic lamina, purified from the media layer of donor blood vessels, has 
recently been shown to possess anti-inflammatory and anti-thrombogenic properties. 
When exposed to arterial blood flow, the elastic lamina elicits lower platelet and 
monocyte activation, thrombosis, and smooth muscle cell proliferation than collagen-
containing blood-contacting surfaces14-17. This has raised the prospect that the elastic 
lamina may substitute for a confluent endothelium in engineered acellular vascular grafts. 
However, despite highly promising early results with elastic lamina scaffolds, there has 
been a lack of progress incorporating this material into vascular grafts. This may be 
attributed to the high cost and low yields of synthetic elastin and recombinant 
tropoelastin18-20. Another significant hurdle is elastin's relative insolubility, precluding the 
polymerization of native elastin by common solvent deposition or electrospinning 
methods21. Recent studies on the inclusion of elastin in polymeric vascular grafts have 
focused on soluble human recombinant tropoelastin electrospun directly into the polymer 
fiber scaffold20, 22 or soluble elastin derived from bovine ligamentum nuche23, also 
electrospun directly into the scaffold. In the present study, we have purified native elastic 
lamina scaffolds from rat donor arteries, thereby circumventing these serious challenges 
while maintaining the native architecture and biological properties of the elastin matrix. 
Unfortunately, the decellularized elastic lamina purified from donor arteries is easily torn, 
lacks mechanical strength, and retains regularly segmented holes due to side-branching. 
In this study, we have undertaken a materials selection process to identify polymeric 
materials that can adhere to the elastic lamina and provide mechanical integrity and 
structural support. We began our development work by employing polyglycolic acid 
(PGA) and poly(ʟ-lactic acid) (PLLA) polymers, which are widely used and well 
characterized24-28, as a proof-of-concept. Both PGA and PLLA are biodegradable 
aliphatic polyesters. PGA has a degradation time of approximately 2 to 4 weeks, while 
PLLA will degrade over a period of several months to several years. Both PGA 
(45−55%) and PLLA (37%) are considered semi-crystalline materials25, 28-29. 
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Subsequently, polycaprolactone (PCL), polyether urethanes (PEUs), and polycarbonate-
urethanes (PCUs) were selected for evaluation due to their well-accepted 
biocompatibility, hydrophobicity similar to that of the elastic lamina, and mechanical 
properties similar to those of the arterial tissue of the host (Table 4.130-36)37-42. We then 
evaluated the best performing hybrid vascular graft out to 21 days, in vivo. 
Table 4.1. Properties for hybrid vascular graft polymer selection. Summary of properties for 
selected polymers. Standard deviations are given in parenthesis when the data was available. NDA 
signifies that no data were available. Where there are no references listed, values were obtained 
from the manufacturer’s data sheet. 
 Structure 
Ultimate Tensile 
Strength (MPa) 
Ultimate Elongation 
(%) 
Wetting Angle 
(degrees) 
PGA Aliphatic 60−99.733 1.5−2033 70.334 
PLLA Aliphatic 50(2.4)–55(0.5)30-31 2.1(0.1)−8.0(0.2)30-31 82(2.3)32 
PCL Aliphatic 25.135 >45035 6937 
PCU 3585A Aliphatic 57.23 425 82.143 
PCU 4085A Aliphatic 62.05 400 82.143 
PEU SG80A Aliphatic 39.9939 66039 NDA 
PEU 1074A Aromatic 41.37 550 8236 
PEU 1085A Aromatic 48.26 450 NDA 
 
4.3. Materials & Methods 
4.3.1. Aorta Specimen Collection 
All animal work was approved by Michigan Technological University’s Internal Animal 
Care and Use Committee (IACUC; #380482-12). Rat thoracic aortas used as donor tissue 
were collected from Sprague Dawley rats (Harlan Laboratories; Indianapolis, IN) 
euthanized with 5% inhaled isoflurane. The diaphragms were punctured, and the hearts 
were removed to ensure death. Thoracic aorta segments of ~30 mm in length were 
isolated, excised, and stored in phosphate buffered saline (PBS) (pH 7.4) at 4°C for later 
use. 
4.3.2. Polymers & Solvents 
PGA was purchased from Polysciences, Inc. (Warrington, PA). PLLA was purchased 
from NatureWorks LLC (Blair, NE). All polyurethanes used were from the Lubrizol 
LifeSciences (Wickliffe, OH) polymer family and are biostable43-44 thermoplastic 
polyurethanes. These included polyether urethanes Tecothane 1074A and 1085A as well 
as Tecoflex SG80A. The polycarbonate urethane compounds used in this project were 
also from the Lubrizol LifeSciences polymer family and included Carbothane 3585A and 
4085A. PBS, hexafluoro-2-propanol (HFIP), chloroform, dichloromethane, N,N-
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dimethylacetamide, acetone, Dulbecco’s modified Eagle’s medium (DMEM), fetal 
bovine serum (FBS), penicillin-streptomycin (P/S), and sodium hydroxide (NaOH) were 
all purchased from Sigma-Aldrich (St. Louis, MO). 
4.3.3. Decellularization and UV Treatment of the Elastic Lamina 
Aortic specimens were processed to remove all non-elastin matrixes, leaving a purified 
and decellularized elastic lamina. Briefly, the aortic specimens were placed in a 50 mL 
conical tube immersed in PBS (pH 7.4). NaOH was added to the solution to make a basic 
PBS solution (pH 12.7)14-15. They were then placed into an ultrasonic bath for 4 hours at 
37°C, changing the solution every hour. The aortic specimens were rinsed in PBS (pH 
7.4) to remove residual NaOH. They were then washed in DMEM with 10% (v/v) FBS 
and 1% (v/v) P/S for 48 hours at 4°C to remove cellular fragments and residual DNA 
material. 
The elastic lamina matrix was modified by irradiating the outer matrix layer with 
ultraviolet (UV) light. UV treatment to cross-link natural matrixes has been described 
previously45. Contrary to chemical methods of cross-linking, irradiation based treatment 
does not incorporate cytotoxic compounds into the matrix46. Some groups have reported 
limited degradation of matrix components after UV treatment47. Processed segments were 
mounted on 304 stainless steel mandrels (outer diameter of 1.65 mm) and UV irradiated 
with 380 ± 20 nm radiation at 1.5 W/cm2 (Phoseon Technology; Hillsboro, OR) for 2 
hours. The UV source was placed 6 cm above the specimens. The specimens were rotated 
90 degrees every 30 minutes to ensure even exposure. A PBS (pH 7.4) bath was used to 
keep the specimens hydrated. The elastic lamina scaffolds were allowed to dry for 48 
hours after UV treatment. 
4.3.4. Polymer Coating of the Elastic Lamina 
The UV-treated elastic lamina scaffolds were coated in 1% (w/w) solutions of the 
selected solvent/polymer combination, listed in Table 4.2. An airbrush (Iwata Eclipse; 
Portland, OR) was used to spray-coat the scaffold with the chosen polymer solution. The 
airbrush was fed at 15 psi from a dry, compressed air source. The scaffold was coated 
with 500 μL of polymer solution at a distance of 10 cm from the brush tip. The vessels 
were allowed to dry overnight prior to electrospinning. Polymer adhesion to the elastic 
lamina was evaluated by spray coating a sample of the UV-treated elastic lamina with 
each polymer and soaking the samples in PBS (pH 7.4) for 5 days at room temperature. 
The PBS-immersed specimens were qualitatively examined under a stereomicroscope to 
identify the presence of delamination. 
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Table 4.2. List of polymers and solvents used in the fabrication of hybrid grafts. Summary of 
polymer/solvent combinations used throughout chapter 4. 
 Polymer Solvent Polymer Weight (%, w/w) 
Vessel Coating PGA Hexafluoro-2-propanol 1 
Vessel Coating PCL Acetone 1 
Vessel Coating PEU 1074A N,N-Dimethylacetamide 1 
Vessel Coating PEU 1085A N,N-Dimethylacetamide 1 
Vessel Coating PEU SG80A N,N-Dimethylacetamide 1 
Vessel Coating PCU 3585A N,N-Dimethylacetamide 1 
Vessel Coating PCU 4085A N,N-Dimethylacetamide 1 
Electrospinning PLLA Chloroform/Dichloromethane 8 
Electrospinning PEU 1074A Hexafluoro-2-propanol 5 
 
To provide structural support, electrospun fibers were deposited over the polymer coated 
elastic lamina scaffolds. Electrospinning needles were purchased from Beckton, 
Dickinson & Co (Franklin Lakes, NJ). For the constructs coated in PLLA, an 8% (w/w) 
solution of PLLA was prepared in equal masses of chloroform and dichloromethane. For 
the samples coated in the polyurethane based materials, a 5% (w/w) solution of PEU 
1074A dissolved in HFIP was used. Electrospinning of the PLLA fibers was performed 
between 33% and 37% relative humidity, with a solution feed of 2 mL/h through a 22 
gauge needle at a distance of 4.5 cm from the needle tip. The accelerating voltage used 
was 17 kV, and the 1.65 mm diameter mandrel rotated at 2,500 rpm during collection. 
The polyether urethane samples had similar parameters, however the flow rate was 
decreased to 0.5 mL/h due to the change in solvent to HFIP. The samples were 
electrospun for 10 minutes to create the specific layer thickness and fiber density. The 
samples were treated with ethylene oxide for 12 hours in an Anprolene AN74i sterilizer 
(Haw River, NC) prior to implantation. All samples were hydrated in sterile saline for ~5 
minutes prior to surgery to prevent fractures during manipulation. 
4.3.5. Electron Microscopy 
Field emission scanning electron microscopy (FESEM) was used to examine the 
processed elastic lamina scaffolds and engineered vascular grafts using a Hitachi S-4700 
field emission electron microscope (5kV accelerating voltage; 10 μA beam current; 
Tokyo, Japan). Specimens were prepared for imaging by allowing them to air dry. Final 
dehydration was accomplished while under vacuum in the sputter coater. Specimens were 
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sputter coated with 5 nm of Pt/Pd on a Hummer 6.2 sputter coater (Anatech, Ltd.; 
Denver, NC), and were stored in a desiccator prior to imaging. 
4.3.6. Electrospun Fiber Characterization 
Electrospun fibers (n = 3) were characterized manually using NIH ImageJ software after 
imaging on the electron microscope. Fiber diameters were determined by manually 
measuring individual fibers under high magnification. Fiber densities were determined by 
drawing a horizontal line in the image and counting the number of fibers present over the 
total length of the line. 
4.3.7. Burst Pressure Testing 
Vascular graft samples (n = 4) were mechanically tested to failure through burst pressure 
measurement. To perform the burst pressure testing, samples were fixed to hollow 304 
stainless steel mandrels (1.65 mm outside diameter) with Dow Corning Silastic tubing 
(0.3 mm i.d., 0.64 mm o.d.; Midland, MI). The far end of the distal mandrel was capped 
following the removal of air from the apparatus. The hydrostatic pressure was recorded 
on a Fisher Scientific vacuum gauge (Pittsburgh, PA), while videos of the vessels during 
the test were recorded on a Nikon D3200 DSLR camera (Melville, NY). PBS (pH 7.4) 
was pumped into the vessel at a fixed rate of 300 μL/min by a syringe pump (Kent 
Scientific Genie Plus; Torrington, CT). 
4.3.8. Mechanical Analysis 
The electrospun polymer layers of the vascular grafts were mechanically tested in 
monotonic tension in the longitudinal direction on a Bose Electroforce 3200 series III 
(Eden Prairie, MN) frame with a 2 kg (19.6 N) load cell. Tubular samples were cut open 
longitudinally to produce sheets, which were fixed in Bose low force grips. The Bose 
Electroforce 3200 used in this work had a 6 mm travel limit during tensile testing. Thus, 
PLLA electrospun samples were tested to failure while the highly elastic PEU 1074A 
electrospun fibers were tested up to the limit of the testing frame. Values affected by 
these limitations are denoted within the paper. Mechanical data are presented as an 
average of six samples ± standard deviations. Data were analyzed in Matlab R2014a 
(Mathworks; Natick, MA). 
4.3.9. Surgical Procedure 
Sprague Dawley rats (Harlan Laboratories; Indianapolis, IN) anesthetized with 2.1% 
inhaled isoflurane in oxygen gas were implanted with ~ 6–8 mm long engineered vessels, 
as interpositional vascular grafts, using an end-to-end anastamotic technique described 
previously38. Briefly, the abdominal aorta was carefully isolated and the proximal and 
distal ends were clamped to prevent blood flow. Side branches were identified and tied 
off to prevent blood flow within the clamped aortic segment, prior to the artery being 
severed midway between the two clamps. For the PLLA scaffolds that were evaluated at 
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1 hour and 3 days (n = 1), both distal and proximal ends of the exposed, severed artery 
were treated with heparin in PBS (pH 7.4; 0.5 unit in ~2 μL saline) to reduce blood 
coagulation at the exposed collagen containing arterial wall. However, no heparin or any 
other anti-coagulant was used when the polyurethane based scaffold was implanted for 
either 3 (n = 1) or 21 (n = 5) days. The vessel constructs were engrafted with 15–20 
interrupted suture stitches (10-0 nylon suture) at each end. Blood flow was reestablished, 
and the grafts were evaluated for leakage. Upon re-establishment of blood flow, pulsation 
was observed in the host artery, both proximally and distally to the implant. The abdomen 
was either kept open, in the case of the 1 hour PLLA specimen, or closed using a 
combination of sutures (for muscle) and staples (for skin), and the rat was allowed to 
recover for 3 or 21 days. The rats were observed for several minutes following recovery 
to confirm normal mobility in the hind quarters, which further indicated graft patency. 
Animals were sacrificed at the designated end points by increasing the inhaled isoflurane 
concentration from 2.1% to 5% after the animals were fully anesthetized. The implant 
site was carefully isolated, and the vessels were evaluated for vascular tone and blood 
flow. Again, pulsation was observed in the host artery surrounding the graft. Then, under 
deep anesthesia, the diaphragms were punctured, the chest cavity was opened, and the 
heart was removed to ensure death. The grafts were collected with host artery connected 
at both the distal and proximal ends. A longitudinal cut was made in the collected graft to 
expose the internal lumen for imaging the graft surface for the single 1 hour and two 3 
day grafts. The five 21 day grafts were left intact and gently syringe perfused with 
freezing medium to both confirm patency and facilitate cryo-sectioning. The samples 
were surrounded with Polyfreeze freezing medium (Sigma Aldrich; St. Louis, MO), snap 
frozen in liquid nitrogen, and stored at -80°C until cryo-sectioning. A 21 day implant 
duration reflects the standard practice for early phase vascular graft development22. 
4.3.10. Histological Preparation and Imaging 
Processed elastic lamina scaffolds were imaged on an Olympus BX-51 microscope 
(Waltham, MA) to confirm decellularization and decollagenization prior to UV treatment, 
using both a fluorescent 4',6-diamidino-2-phenylindole (DAPI)  nuclear stain and a 
Verhoeff’s - Van Gieson (VVG) stain. Explanted samples were additionally stained with 
hematoxylin & eosin (H&E). All components for staining were purchased from Sigma-
Aldrich (St. Louis, MO), with the exception of the Gill’s #3, which was purchased from 
Leica Biosystems (Buffalo Grove, IL). Specimens were sectioned on a Microm HM550 
cryostat (Microm International GmbH; Walldorf, Germany) at a thickness of 10 μm and 
fixed in ethanol for 60 seconds. 
The samples were rinsed in PBS (pH 7.4) three times prior to undergoing staining for 
DAPI imaging or VVG staining. For DAPI staining of cell nuclei, 3 μL (5 mg/mL) of 
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diluted DAPI was added to the samples in 1 mL of PBS (pH 7.4). The VVG staining 
procedure followed a protocol published by the American Society of Clinical 
Pathologists48. Verhoeff’s solution was prepared by mixing 30 mL of hematoxylin (Gills 
#3), 12 mL of 10% (m/v) ferric chloride, and 12 mL of Lugol's iodine. Gills #3 turns the 
elastic lamina brown. The Verhoeff’s solution that was used produced a brown color 
change specific to elastin-containing matrixes. Tissue sections were placed into 
Verhoeff's solution for one hour, and then rinsed twice with deionized water. Sections 
were then differentiated in a 2% (m/v) ferric chloride solution. The sections were again 
rinsed with distilled water, treated with 5% (m/v) sodium thiosulfate for one minute, and 
rinsed in tap water three times. Sections were counterstained in Van Gieson's solution for 
30 seconds, differentiated in 95% alcohol, dehydrated with absolute ethanol, and cleared 
in xylene substitute before mounting and imaging. 
Explanted samples were additionally stained by H&E. Ethanol fixed cross sections were 
washed in three changes of PBS (pH 7.4) for 5 minutes each, followed by a wash in 
deionized water for 5 minutes. The samples were then placed in Gills #3 for 5 minutes to 
fully stain the sections. The slides were then differentiated by dipping five times into a 
solution of hydrochloric acid in deionized water (pH 2). Once differentiated, the slides 
were placed into deionized water for 1 minute to blue them. The blued samples were 
placed into two changes of 95% ethanol for 5 minutes per change. Eosin Y (0.25%) was 
then used to counterstain the sections for 30 seconds, after which they were dehydrated in 
absolute ethanol and cleared in xylene substitute. The samples were then mounted and 
imaged. 
4.4. Results 
4.4.1. Decellularization and Stabilization of Elastic Lamina 
Histological analysis of the processed aortic specimens demonstrated successful isolation 
of the elastic lamina. The elastic lamina was clearly defined (shown as brown fibers) with 
no collagen-bearing matrixes observed between the layers of elastic lamina or inner/outer 
vascular layers (Figure 4.1A, B). The processed specimens were found to be completely 
devoid of cell nuclei (Figure 4.1C, D). Success of the decellularization processing was 
further confirmed by electron microscopy. FESEM images of the processed elastic 
lamina depict an intact elastic lamina matrix composed of several layers, with 
interconnecting fibers (Figure 4.2). The internal surface of the elastic lamina is irregular, 
with many crevices. The thickness of the elastic lamina varied between 40 and 80 μm. 
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Figure 4.1. Decellularization of rat thoracic aortas. Representative images for native and 
decellularized/decollagenized arterial cross-sections. (A, B) The elastic lamina stained with VVG to 
show collagens present in the unprocessed vessel (A) and their absence in the processed tissue 
(B). (C, D) Cell nuclei were stained with DAPI to show cellularization of the elastic lamina and 
adventitial layers of the native artery (C) and the absence of cell nuclei after decellularization (D). 
The blue fibers in (C) and (D) are due to inherent fluorescence from the elastic lamina, not from 
DAPI staining. 
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Figure 4.2. Images of decellularized elastin products. FESEM images of the decellularized elastin 
scaffold. (A) External view. (B) Internal view. (C) Internal surface/scaffold wall. (D) Magnified image 
of the internal surface from window C. (E) Magnified image of the external surface and scaffold 
edge. (F) Magnified image of the external surface/scaffold wall. 
Elastic lamina matrixes that were UV-treated for two hours exhibited more favorable 
mechanical properties relative to the non-treated matrixes. After treatment, the 
decellularized elastin vessels were able to support themselves partially open. 
4.4.2. Aortic Engraftment Using Only UV-Treated Elastic Lamina 
After determination that UV treatment for 2 hours improved the material handling 
properties and mechanical strength, an early attempt was made to engraft a segment into 
the rat abdominal aorta, without polymeric support. Unfortunately, as the sutures were 
placed and tightened, tears appeared in the elastic lamina scaffold (data not shown). This 
result suggested the treatment decreased the elastic lamina’s resistance to tearing. 
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4.4.3. Early Hybrid Grafts 
This early engraftment demonstrated the need for external mechanical support of the 
elastin matrix via polymer coating. To accomplish this, a spray-coated layer of PGA in 
HFIP was deposited on the external elastic lamina surface. PGA acted as a transitional 
layer to connect an electrospun PLLA scaffold to the elastic lamina, while improving the 
graft’s mechanical properties. Once dried, PLLA electrospun fibers were deposited over 
the PGA surface. These fibers were found to be unaligned. The fibers were found to have 
widely varying diameters and orientations, which promotes suturability and mechanical 
isotropy in the electrospun fiber layer. The innermost fiber layer contained relatively 
small diameter fibers with few defects. The outermost layer generally contained larger 
diameter fibers, with significant necking and branching, indicative of poor grounding of 
the mandrel due to fiber buildup. Pore sizes between the fibers appeared to vary on the 
basis of the layer in which they were deposited (Figure 4.3A-C). Large pores between 
fibers are anticipated to permit cellular infiltration. 
An FESEM image of the fabricated construct demonstrated sufficient adhesion to 
promote graft stability between the deposited PGA layer and the PLLA fibers, even after 
several cycles of hydration and dehydration (Figure 4.3C). It is important to note that the 
FESEM sample preparation caused slight delamination of the PGA layer from the elastic 
lamina surface due to the requisite dehydration (Figure 4.3D). This effect was not 
observed during processing or surgery, but suggests the adhesion between these layers 
could be improved. Despite this shortcoming, the overall mechanical integrity of the 
hybrid construct was much preferable relative to that of the only UV-treated elastic 
lamina. 
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Figure 4.3. Images of an early elastin hybrid graft. FESEM images showing the fiber morphology 
of the PGA/PLLA vascular graft. (A) Wide view of the intact graft. (B) Magnified view of the graft. 
(C) Image of the elastic lamina contacting side of the fiber layer without the elastic lamina. (D) Edge 
view of the assembled graft with polymer layers and elastic lamina. Asterisks (*) denote 
delamination due to the FESEM preparation protocol. n = 2. 
4.4.4. Aortic Engraftment of PGA/PLLA Hybrid Constructs 
After observation of good suturability and layer adhesion, the PGA/PLLA/elastic lamina 
constructs were interposed and sutured into the rat abdominal aorta. The luminal elastic 
lamina surface of a representative graft prior to implantation is shown in Figure 4.4A–B. 
The graft was collected for analysis after either one hour (Figure 4.4C–D) or 3 days 
(Figure 4.5) post implantation (n = 1 per time point). The one hour sample was free from 
obvious signs of blood coagulation. The 3 day vessel also showed no obvious signs of 
blood coagulation. Staining confirmed the absence of cellular infiltrates into the elastic 
lamina matrix (Figure 4.5C–G). A comparison between the 3 day graft and the native 
artery at the graft/artery interface demonstrates the absence of cell nuclei in the fabricated 
grafts as compared to the native artery, as well as the continuous surface of the elastic 
lamina up to the endothelialized host artery (Figure 4.5G, H). There was evidence of 
modest blood coagulation at the suture line, which is attributable to blood contact with 
either the suture material or PGA/PLLA that became exposed during suturing. 
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Figure 4.4. Implantation of a preliminary elastin hybrid vascular graft. (A, B) Luminal view of the 
PGA/PLLA graft prior to implantation. (C) The PGA/PLLA vascular graft is shown prior to harvest, 
at 1 hour post-surgery. (D) The collected graft’s luminal surface is exposed to show absence of 
obvious coagulated blood. 
63 
 
 
Figure 4.5. Histology of a preliminary elastin hybrid graft. Imaging and characterization of the 3 day 
PGA/PLLA vascular graft. (A) Depiction of the vessel prior to collection at 3 days post-surgery. (B) 
The graft’s luminal surface is exposed to demonstrate absence of obvious signs of blood 
coagulation. (C, D) H&E staining of the cross sectioned vessel, showing open lumen with minimal 
thrombus, as well as absence of cellular infiltration into the elastic lamina and polymer layers. (E, 
F) Verhoeff’s Van-Gieson staining of the cross sectioned vessel identifying the location of the 
processed elastic lamina and demonstrating continued absence of cells. (G) H&E staining at the 
graft-vessel junction. (H) Verhoeff’s Van-Gieson staining at the graft-vessel junction. In G and H, 
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‘e’ identifies the acellular elastic lamina of the engineered graft, ‘nv’ identifies the cellularized elastic 
lamina of the native vessel, and ‘p’ identifies the acellular polymeric material. 
Although the PGA/PLLA/elastic lamina graft performed well overall, the graft was found 
to be excessively brittle, as the PLLA layer cracked and flaked to some extent during 
suturing. Furthermore, adhesion defects revealed by SEM processing (Figure 4.3D) 
suggested that the PGA layer was not able to strongly adhere to the elastic lamina. For 
this reason, it was necessary to explore other polymeric biomaterials that could better 
serve as mechanical reinforcement to the elastic lamina. 
4.4.5. Fabrication and Performance of Improved Hybrid Grafts 
Polymer selection to identify materials with superior performance began by identifying 
well-characterized polymers with lower crystallinity and higher elastic moduli relative to 
PGA and PLLA. Table 4.1 lists the relevant properties of the considered materials. Most 
of the selected materials were hydrophobic to some degree, and all possessed high 
elongations to failure (≥ 400%). The hydrophobicity of some materials was anticipated to 
assist in adhesion to the hydrophobic elastic lamina. High elongations to failure implied 
that these materials were less likely to crack during processing and surgical implantation. 
 Polymer coated samples were examined for delamination after hydration in PBS (Figure 
4.6). Both PCL and PEU SG80A suffered from severe delamination and were therefore 
eliminated from consideration. Further delamination analysis was performed by 
dehydrating the hybrid grafts and examining an example of each in cross section (Figure 
4.7). Again, PCL and PEU SG80A scaffolds were found to adhere poorly to the elastic 
lamina. Minor delamination was also seen with PCU 4085A. Magnified images of 
scaffolds were collected for closer inspection of the polymer/elastic lamina interface 
(Figure 4.8). PCL was completely delaminated from the elastic lamina layer. PEU 1085A 
exhibited adequate adhesion between the polymer/elastin layers. PEU SG80A was 
completely delaminated (elastic lamina shown in Figure 4.8C and separated polymer 
coating shown in Figure 4.8D). PCU 3585A was well adhered to the elastic lamina. In 
this case, the polymer layer was difficult to distinguish from the elastin. PCU 4085A was 
delaminated in several areas of the sample. Due to this result, PCU 4085A was eliminated 
from further evaluation. PEU 1074A was found to have excellent adhesion to the elastic 
lamina matrix. 
65 
 
 
Figure 4.6. Evaluation of polymer delamination in elastin hybrid grafts. Polymer coated elastic 
lamina cross sections immersed in PBS solution and imaged with a stereoscope. (A) PCL. (B) PEU 
SG80A. (C) PCU 4085A. (D) PEU 1085A. (E) PCU 3585A. (F) PEU 1074A. Red arrows in A and B 
identify sites of delamination between the elastic lamina and polymer coating. n = 2 per polymer 
coating. 
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Figure 4.7. Images of polymer delamination on elastin hybrid vascular grafts. FESEM images of 
polymer coated elastic lamina specimens. (A) PCL. (B) PEU SG80A. (C) PCU 4085A. (D) PEU 
1085A. (E) PCU 3585A. (F) PEU 1074A. Red arrows in A, B, and C identify sites of delamination 
between the elastin and polymer coating. n = 2 per polymer coating. 
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Figure 4.8. Images of various polymer/elastin interfaces. High magnification FESEM images of the 
polymer/elastic lamina interface for (A) PCL, (B) PEU 1085A, (C, D) PEU SG80A, (E) PCU 3585A, 
(F) PCU 4085A and (G) PEU 1074A. The thickness of each layer is labeled in each panel. n = 2 
per polymer coating. 
The successful polymers (PEU 1074A, PEU 1085A, and PCU 3585A) were then 
evaluated in a suture pullout test to provide information on how they would perform 
during suturing. The elastic lamina was spray coated with the three remaining polymers 
and electrospun with PLLA fibers and underwent a suture pullout event followed by 
FESEM imaging of the failure surfaces (data not shown). An ideal suture pullout should 
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reveal good elasticity and plastic deformation, but also good resistance to suture pullout. 
PEU 1074A resisted suture pullout without exhibiting brittle fracture. PEU 1085A failed 
with low resistance and was consequently dismissed from consideration. PCU 3585A 
failed by brittle fracture and was also removed from further consideration. Therefore, 
PEU 1074A was deemed the best material of those considered for this application. 
4.4.6. Polyether urethane (PEU 1074A) Hybrid Graft Implantation 
Prior to implantation, the PEU 1074A/elastic lamina conduit was further improved by 
electrospinning fibers using PEU 1074A dissolved in HFIP (Figure 4.9) in place of the 
electrospun PLLA fibers used in previous tests. This modification was found to vastly 
improve the interfacial adhesion between the polymer layers, and also resulted in better 
quality fibers in the fully assembled vascular graft. After three days post-implantation (n 
= 1), the graft was excised and characterized histologically (Figure 4.10). A longitudinal 
cut made to expose the luminal graft surface revealed a small region with attached 
coagulated blood. This material was loosely adhered to the suture line at the distal end of 
the graft but was not attached to the elastic lamina surface. An H&E stain showed 
significant cellular infiltration into the electrospun PEU 1074A fibers, as well as a thin 
thrombus layer near the suture site. The thrombus layer thickness was well below 10 μm 
at most locations away from the suture line. 
 
Figure 4.9. Images of a finalized hybrid elastin vascular graft. Elastic lamina coated in PEU 1074A 
with electrospun PEU 1074A fibers deposited externally. (A, B) Cross sectional view of the pre-
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implantation specimen, demonstrating good adhesion between the layers. (C, D) Longitudinal view 
of the pre-implantation specimen’s fibers, showing unexpected partial longitudinal fiber alignment. 
Both polymers were dissolved in HFIP for coating. n = 2. 
 
Figure 4.10. Histology of short-term hybrid elastin vascular grafts. Characterization of the 3 day 
PEU 1074A vascular graft. (A) The PEU 1074A graft is shown prior to collection. (B) The excised 
graft is opened to expose the luminal surface, showing near complete absence of obvious blood 
coagulation. (C) H&E staining of a vessel section near the suture site demonstrates modest 
thrombus formation and an extensive cellular infiltration into the polymer layer ‘p’, whereas the 
elastic lamina ‘e’ remains acellular. (D) Magnified view of a more representative thrombus layer, 
collected from a location midway along the vessel. (E) Verhoeff’s Van-Gieson staining of the 
explanted vessel shows the graft-vessel junction. ‘nv’ represents the native vessel, ‘e’ represents 
the elastin graft, ‘p’ shows the polymer, and ‘c’ is the collagenous layer. A continuous elastic lamina 
layer is present up to the host artery. 
After 21 days post-implantation (n = 5), the grafts were excised and characterized (Figure 
4.11). All five grafts were patent, with clear signs of arterial pulsation evident at both 
distal and proximal host locations. H&E stains verified patent lumens as well as the 
formation of a relatively thin neointima on the luminal surface of the grafts (Figure 
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4.11B). Some wrinkling of the elastic lamina and artificial detachment of the polymer 
coating due to cross sectioning is evident. Typical low (Figure 4.11C) and high (Figure 
4.11D) neointimal tissue thicknesses are shown. Delamination of the polymer coating 
from the elastic lamina was commonly detected post cross sectioning (Figure 4.11B, D). 
However, delamination is unlikely to have been a dominant factor in situ, as excellent 
interfacial adhesion was seen at the sites of pores within the elastic lamina (Figure 
4.11E). These sites provide direct contact between the polymer and blood flow/pressure 
and are therefore natural nucleation sites for delamination, if it were to occur. In rare 
cases, cells could be seen residing within the elastic lamina (Figure 4.11D). Sites of 
wrinkling (Figure 4.11B) and pores (Figure 4.11E) were associated with an increased 
neointimal thickness. 
 
Figure 4.11. Histology of long-term hybrid elastin vascular grafts. Characterization of the 21 day 
PEU 1074A vascular graft. (A) The PEU 1074A graft is shown prior to collection. (B) H&E staining 
of a vessel transverse section demonstrates modest neointimal formation on both sides of the graft 
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(top and bottom of image) and an open lumen. (C) Magnified view of a representative low thickness 
neointimal layer. Polymer coating can be seen adhering to the elastic lamina. (D) Magnified view 
of a representative high thickness neointimal layer. Cell nuclei can be seen to have migrated into 
the elastic lamina. Dark green stars identify lumen, red stars identify polymer, and yellow stars in 
images identify elastic lamina. Light green arrows identify cells within the elastic lamina in (D). The 
light green arrow in E identifies a pore in the elastic lamina, which is created by arterial side 
branching at the donor site. Yellow arrows in B and E identify protrusion of the neointimal layer into 
the lumen due to elastic lamina defects. Blood flow proceeds left to right in (B) and (E). The scale 
bar shown in (B) is the same for (E). 
4.4.7. Mechanical Evaluation of Hybrid Vascular Grafts 
Characterization of the electrospun PEU 1074A fibers and mechanical properties of the 
graft are shown in (Table 4.3). We found burst pressures to be well in excess of 
physiological demands and in accordance with other experimental vascular grafts49-51. In 
one specimen, the elastic lamina was seen to delaminate from the reinforcing polymer at 
~800 mmHg, prior to burst failure of the polymer layer. Notably, the elastic lamina did 
not delaminate from any of the other specimens, despite the presence of large pores in 
this layer due to extensive arterial side-branching at the donor site. Thus, the elastic 
lamina and polymer layers exhibited excellent interfacial adhesion. 
Table 4.3. Comparison of hybrid elastin vascular graft properties. Table 4.3 summarizes the 
physical properties of the vessels and provides data for the native saphenous vein for comparison 
purposes. Values are reported with standard deviations where available. n = 4 for burst pressure 
and wall thickness measurements. n = 3 for fiber diameter and density measurements. 
 
Wall Thickness 
(μm) 
Burst Pressure 
(mmHg) 
Fiber 
Diameter (μm) 
Fiber Density 
(fibers/mm) 
PEU Coated Elastin N/A 200 ± 29 N/A N/A 
Vascular Grafts 106 ± 42 990. ± 110 1.7 ± 0.7 200 ± 80 
Saphenous Vein 25052 1600–250052 N/A N/A 
 
Due to the negligible contributions of both the elastic lamina and spray-coated layer to 
the mechanical properties of the vessel, tensile testing was restricted to the two different 
electrospun fibers used to construct all of the hybrid vascular grafts. A representative 
stress-strain plot for both the electrospun PLLA and PEU 1074A fibers can be seen in 
Figure 4.12. While the relatively brittle character of the PLLA fibers allowed all samples 
to be evaluated to failure, the exceptional elasticity of the PEU 1074A fibers prevented 
the collection of failure data for this material. The average elastic modulus of the 
electrospun fibers was 64 ± 35 MPa for the PLLA samples and 1.4 ± 0.80 MPa for the 
PEU 1074A samples. The elongation to failure for PLLA was 10. ± 4.1%. The average 
observed elongation of the PEU 1074A without failure was 200 ± 24%. These data are 
summarized in Table 4.4. 
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Figure 4.12. Mechanical testing of hybrid elastin vascular grafts. The representative plots of stress 
vs. strain for both the electrospun PLLA (black) and PEU 1074A (red) can be seen above. Due to 
the limits of the mechanical tester, the PEU 1074A samples were not able to be evaluated to failure. 
Table 4.4. Summary of hybrid elastin vascular graft mechanical testing. Table 4.4 summarizes the 
mechanical properties of the electrospun PLLA and PEU 1074A fibers. 
 Observed Elastic Modulus (MPa) 
Observed 
Elongation (%) 
Poly (ʟ-lactic acid) 64 ± 35 10. ± 4.1 
Polyether Urethane 1074A 1.4 ± 0.8 200 ± 24 
Native Saphenous Vein 1.6 ± 0.05753 1754 
 
4.5. Discussion 
Here, we have constructed a novel vascular graft by supporting an elastic lamina blood-
contacting surface with polymeric materials. The graft was easy to manipulate and suture. 
Importantly, the graft avoided significant inflammatory responses and progressive intimal 
hyperplasia, both widely recognized as mediating factors in restenosis. The elastic lamina 
appears to exert suppressive effects on resident cells. This requires receptor-mediated 
signaling mechanisms, which employ a ligand with precise protein structure and 
electrostatic activity15. Thus, it seems that the processing conditions used to construct the 
graft (e.g. NaOH decellularization, UV irradiation, and ethylene oxide treatments) did not 
substantially alter the chemical composition of the elastic lamina. 
An ideal vascular graft should match the mechanical characteristics of the native artery. 
Concurrently, viable vascular grafts must mimic the properties of a native endothelium at 
the blood contacting surface, not provoke an inflammatory response, remain shelf stable 
over extended time periods prior to use, and be easy to handle and suture. The latter 
requirement precludes the presence of cellular fragments or DNA from the donor. It has 
been challenging thus far for the scientific and industrial community to develop a graft 
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that possesses all of these ideal properties. This is mainly due to the challenge of 
mimicking a confluent endothelium on the luminal surface of acellular materials and the 
difficulties in generating universally compatible implant materials from cellularized 
constructs. 
The grafts developed here have a wall thickness and burst pressure similar to those of the 
native saphenous vein, which is a widely used autologous conduit for coronary artery 
bypass grafting. Specifically, the native saphenous vein has a burst pressure of 1600 - 
2500 mmHg and a wall thickness of 250 μm52. While the present vascular grafts exhibit a 
slightly lower average burst pressure of 990. ± 112 mmHg, their wall thickness is less 
than half that of the saphenous vein at 106 ± 42.0 μm. These data would suggest a similar 
mechanical strength for the bulk material. 
Tensile evaluation of the PLLA and PEU 1074A electrospun polymers revealed a clear 
difference in their mechanical properties as the brittle behavior of the PLLA was evident. 
The relative brittleness of PLLA is consistent with tabulated mechanical data presented in 
Table 4.1, which lists PLLA as having among the lowest elongations to failure. In 
contrast, the final polymer used in this work, PEU 1074A, exhibited exceptional elastic 
behavior in both burst pressure and tensile tests. Ideally, the selected reinforcing polymer 
for the vascular graft should possess mechanical properties similar to those of native 
blood vessels. The elastic modulus of a typical, non-diseased human coronary artery is 
1.48 MPa55, while the elongation to failure of the human carotid artery is reported as 
105%20. The native saphenous vein demonstrates an elastic modulus of 1.6 ± 0.057 MPA 
and an observed elongation of 17%53-54. Thus, PEU 1074A matches or exceeds the 
mechanical properties of a native small diameter human artery and the current standard 
for their replacement. 
In the case of the present hybrid graft, the main function of the polymeric biomaterials 
(either the biodegradable PLLA or biostable PEU 1074A) is to provide mechanical 
support. In this role, polymeric supporting materials can be optimized with fewer 
concerns for blood-contacting properties, and allow development to move toward 
matching their mechanical characteristics to the native artery. Meanwhile, the elastic 
lamina provides an excellent acellular blood contacting layer, which has been a serious 
limitation of acellular materials to date. Conversely to the polymer materials, the elastic 
lamina may be harvested and processed with little concern for its mechanical 
performance. Thus, the multilayered design of the present engineered acellular vascular 
graft, with a biological layer and a synthetic layer that are each optimized for different 
functions, makes it more feasible to achieve the overall performance goals. Such a graft, 
because it is acellular, can be developed specifically as a xenograft from the artery of any 
donor animal and be implanted into any recipient. It is also shelf stable and can be 
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quickly hydrated in the operating room, and therefore can be stocked to meet the urgent 
needs of surgeons and patients. 
During the course of evaluation, a number of defects in these experimental grafts became 
evident. These included rare cases of cell migration into the elastic lamina and regions of 
delamination between the different polymers and elastic lamina. Although we have 
achieved excellent results with the present processing conditions, the processing steps are 
amenable to improvements. Further refinement may result in a reduced neointimal tissue 
development relative to what was found here. For example, alternative techniques to 
decellularize and purify the elastic lamina could be employed to better preserve the 
structural and chemical integrity of its constituent proteins, which serve as ligands for the 
receptor-mediated signaling events that suppress cellular activity. The presence of cells 
within the elastic lamina at rare sites in the 21 day grafts suggests that processing 
conditions may have locally altered the chemical structure of the elastic lamina. Altering 
the molecular weight or solvent concentration in polymer processing may improve 
adhesion between the PLLA and elastic lamina and provide a testable, biodegradable 
graft to compare at longer times with the biostable PEU 1074A graft. In addition, 
consistency between batches of vascular grafts would benefit from more automated and 
controlled processing and fabrication conditions. 
While characterizing the hybrid grafts, we observed longitudinal alignment of 
electrospun fibers in the PEU 1074A graft. This fiber orientation will cause the material 
to be resilient when stretched along the longitudinal direction, but may create deficiencies 
in resisting large hoop stresses. While this introduces some concerns, the grafts were still 
able to resist arterial pulsatile pressure and retain sutures for up to 21 days. Future work 
with this material will aim to provide a more uniform distribution of fiber alignment with 
the ultimate goal of achieving mechanical isotropy in the structural coating. 
It is important to note that the low degree of thrombus formation in the elastic 
lamina/PEU 1074A graft was similar to that of the elastic lamina/PGA/PLLA graft at the 
3 day time point. This is likely due to the excellent hemocompatibility of the elastic 
lamina, and confirms that the hybrid conduit design offers flexibility in polymer 
selection. Surprisingly, although the PLLA electrospun fiber layer was thicker than that 
of the PEU 1074A fibers, there was markedly more cellular infiltration seen within the 
PEU 1074A fibers. This is likely due to a combination of differences in porosity, pore 
size distribution, fiber diameter, hydrophobicity/hydrophilicity, and the associated degree 
of swelling between the two constructs. Because cellular infiltration into the graft is 
necessary for integration of the material, the ability of cells to infiltrate and the type of 
cell infiltrates represent an additional consideration for polymer selection and 
modification, especially if biodegradable constructs are being considered. 
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Future work aimed at improving the performance of the vascular graft could be directed 
toward clarifying the key factors that regulate interfacial adhesion between the polymer 
and elastic lamina. Such an assessment may reduce the reliance upon bulk properties for 
material selection. Future experiments with longer term in vivo implantations (between 6 
months and 1 year) will enable a more thorough characterization of the long-term 
biocompatibility of the graft. Lastly, optimization of the donor artery processing 
conditions may reduce chemical and physical alterations of the elastic lamina from its 
native state and better preserve the cell suppressive properties that make this material an 
excellent blood contacting layer. 
4.6. Conclusion 
This work has demonstrated an effective approach for the construction of hybrid vascular 
grafts with natural elastic lamina as blood contacting surfaces. Using simple tissue 
engineering techniques and fabrication methods, a vascular construct has been devised 
that demonstrates promising short term performance as a vascular graft, in vivo. The 
vessel fabricated in this work improves upon current small diameter vascular grafts by 
making use of an elastic lamina blood-contacting layer, which has been shown to be non-
thrombogenic, non-immunogenic, and neointimal hyperplasia resistant. As compared to 
experimental vascular grafts that rely upon synthetic elastin or elastin-like polypeptides, 
our approach decellularizes widely available donor tissue. The arteries of larger animals 
could serve as donors for human applications. This approach minimizes the costs, 
simplifies the fabrication process, and preserves the native architecture and biological 
properties of the elastic lamina. The use of synthetic polymers to provide mechanical 
reinforcement is another innovative feature that allows for extensive refinement of the 
mechanical properties in the final product. Further innovation may involve the 
incorporation of drug releasing components into the polymeric material. 
The positive results of this work open the door for further development of the 
decellularization methods, polymers, coating techniques, and electrospinning process. A 
shelf-stable vascular graft containing a natural and intact elastic lamina that reduces the 
natural tendency of the host environment to respond to vascular engraftment with platelet 
activation, excessive thrombogenesis, and intimal hyperplasia may provide a new 
direction for developing small diameter vascular grafts, particularly for coronary artery 
bypass procedures. 
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Chapter 5: Synthesis and Characterization of the Novel Nitric Oxide (NO) 
Donating Compound, S-nitroso-N-acetyl-D-penicillamine Derivatized 
Cyclam (SNAP-Cyclam)2 
 
5.1. Abstract 
Nitric oxide (NO) has been heavily studied over the past two decades due to its multiple 
physiological functions and its potential therapeutic promise. Of major interest is the 
desire to fabricate or coat implanted devices with an NO releasing material that will 
impart the appropriate dose and duration of NO release to positively mediate the 
biological response to the medical device, thereby improving its safety and efficacy. To 
date, this goal has not yet been achieved, despite very promising early research.  
Herein, we describe the synthesis and NO release properties of a novel NO donor which 
covalently links the S-nitrosothiol, S-nitroso-N-acetyl-D-penicillamine (SNAP), to the 
macrocycle, cyclam (SNAP-cyclam). This compound can then be blended into a wide 
variety of polymer matrices, thereby imparting NO release to the polymer system. This 
release can be initiated and controlled by transition metal catalysis, thermal degradation 
or photolytic release of NO from the composite NO-releasing material. SNAP-cyclam is 
capable of releasing physiologically relevant levels of NO for up to 3 months in vitro 
when blended into poly(ʟ-lactic acid) thin films. 
5.2. Introduction 
Nitric oxide (NO) is a short-lived free radical gas with important roles in intracellular 
signaling pathways of diverse physiological systems, ranging from neuronal signaling to 
the regulation of vascular tone and thrombosis1-2. In particular, NO has widespread roles 
in the vascular system, having been shown to inhibit smooth muscle cell migration and 
proliferation3-5, promote endothelial cell growth and proliferation5-7, and inhibit platelet 
activation and inflammation8-9. Although found in many systems, the extremely short 
half-life of NO (less than one second in an oxygenated environment) sharply restricts its 
activity to the vicinity of its production source10-12. These beneficial properties make 
compounds with the ability to sustainably deliver specific levels of NO highly desirable 
for biomedical applications13. Consequently, NO has been heavily investigated in recent 
years as a therapeutic drug for biomedical applications. 
Endogenous NO is produced through several classes of nitric oxide synthases (NOS), 
enzymes that convert L-arginine into L-citrulline and NO14. The major donors reliant on 
the passive release of NO are a class of zwitterions known as diazeniumdiolates9. NO 
donor molecules known as S-nitrosothiols (RSNOs) are also present physiologically in 
several forms, the most common of which is S-nitrosoglutathione10, 15. In addition to 
endogenous forms, RSNOs of varied chemical structures can be synthesized and have 
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been used for passive or controlled NO release, both in vitro and in vivo8, 10. S-
nitrosothiols donate NO in a controlled manner in response to several external factors, 
including transition metal ion catalysis, thermal degradation and photolytic cleavage15-16. 
Photolytic cleavage is the preferred mode of release for in vitro experimentation as the 
dose and duration of NO delivered can be precisely controlled, whereas transition metal 
ion and thermal mediated release are utilized for in vivo applications which do not require 
precise control over the NO release profiles10, 15-16. 
In the present study, a novel NO donor, S-nitroso-N-acetyl-D-penicillamine (SNAP), 
covalently linked to the macrocycle, cyclam (SNAP-cyclam), was synthesized, 
characterized and then used as the NO donor in poly(ʟ-lactic acid) films which showed 
physiologically relevant NO release for 3 months. The self-protected NAP-thiolactone 
can be attached to the secondary amine groups of the macrocyclic base, 1,4,8,11-
tetraazacyclotetradecane (cyclam). This compound is simple to synthesize and shows 
uniquely stable, controllable, long term NO release through mechanisms common to S-
nitrosothiols15-16. The new donor demonstrates promise for long term, stable release of 
NO, and has a wide range of potential applications in polymeric biomaterials and device 
coatings due to its ease of synthesis and the ability to blend the compound into a variety 
of polymeric materials. 
5.3. Materials & Methods 
5.3.1. Synthesis of NAP-Cyclam 
N-acetyl-D-penicillamine, acetic anhydride, chloroform, hexanes, and sodium nitrite 
(99.999% trace metals basis) were obtained from Sigma-Aldrich (St. Louis, MO). 
Pyridine, hydrochloric acid, and sulfuric acid were obtained from EMD Chemicals 
(Gibbstown, NJ). Magnesium sulfate was purchased from Alfa Aesar (Ward Hill, MA). 
1,4,8,11-tetraazacyclotetradecane (99%+) (cyclam) was obtained from Acros Organics 
(Geel, Belgium). 
N-acetyl-D-penicillamine thiolactone (NAP-thiolactone) was prepared according to a 
previously reported method17. Briefly, 5 grams of N-acetyl-D-penicillamine were 
dissolved in 10 mL of pyridine and cooled over ice for one hour. Concurrently, 10 mL of 
pyridine and 10 mL of acetic anhydride were mixed and cooled over ice. After one hour, 
the solutions were mixed and stirred for 24 hours or until the solution turned light red. 
The solvents were then evaporated until only an orange liquid remained. This product 
was then dissolved in chloroform and washed with 1M hydrochloric acid. The organic 
layer was dried with magnesium sulfate, after which the solid was removed by vacuum 
filtration and the liquid collected. The liquid was evaporated to remove the chloroform 
and the remaining solid was suspended in hexanes and the crystalline product collected 
by vacuum filtration. The resultant product was a white, crystalline powder. 
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To prepare NAP-cyclam, equimolar quantities of cyclam and NAP-thiolactone were 
added to a sufficient volume of chloroform to ensure full dissolution. These components 
were allowed to react on a shaker table for 30 minutes. After reacting, the solvent is 
evaporated on a rotary evaporator (Heidolph Laborota 4000; Elk Grove Village, IL). The 
resultant viscous liquid is then vacuum dried for 24 hours, ground and homogenized, and 
vacuum dried for a further 24 hours. The typical recovery is approximately 85% (wt/wt). 
5.3.2. Synthesis of SNAP-Cyclam 
Two nitrosation mechanisms were employed to form SNAP-cyclam. The first method 
utilized tert-butyl nitrite (90%; Acros Organics; Geel, Belgium) as the nitrosating agent, 
while the second method employed sodium nitrite (Sigma-Aldrich; St. Louis, MO). 
Dodecylbenzenesulfonic acid (DBSA) was purchased from Sigma-Aldrich (St. Louis, 
MO). To nitrosate the compound with tert-butyl nitrite, NAP-cyclam was dissolved in 
chloroform. Tert-butyl nitrite was cleaned using 30 mM aqueous cyclam to remove 
copper (II) stabilizing ions. A slight molar excess of cleaned tert-butyl nitrite was added 
to NAP-cyclam in solution. Immediately upon addition, a mint green precipitate formed 
at the surface of the solution. When the vial was shaken, the solution would turn a 
characteristic emerald green. 20 μL of DBSA was added to nitrosate the solution fully. 
Rotary evaporation was used to isolate the resultant green solid, SNAP-cyclam. 
Solid sodium nitrite was also used to nitrosate NAP-cyclam. In a typical nitrosation 
process, NAP-cyclam and a molar excess of sodium nitrite are added to 1 mL of 
deionized water (18MΩ·cm) and shaken to dissolve both solids. 20 μl of concentrated 
(17.8M) sulfuric acid (EMD Chemicals; Gibbstown, NJ) was then injected into the 
solution. The vial was shaken several times to ensure a complete reaction has occurred. 
An emerald green precipitate formed immediately, which was isolated by vacuum 
filtration followed by several rinses in deionized water. The green powder, SNAP-
cyclam, is then vacuum dried. The typical recovery was approximately 64% (wt/wt). 
5.3.3. Copper Chelation Analysis 
Reaction times and product stability of NAP-cyclam were determined using a copper 
chelation assay18. When copper (II) chloride (Alfa Aesar; Ward Hill, MA) is added to a 
solution containing cyclam in chloroform, the solution becomes purple, indicating copper 
chelation by the cyclam has occurred. NAP-cyclam dissolved in chloroform is unable to 
chelate copper. By exploiting this phenomenon, the reaction’s progress can be evaluated, 
and the stability and reaction time of NAP-cyclam was determined. Analysis was 
performed with ultraviolet visible light (UV/Vis) spectroscopy. 
5.3.4. Free Thiol Analysis of NAP-Cyclam 
Free thiol analysis was used to determine the molar ratio of NAP-thiolactone to cyclam in 
NAP-cyclam. The reaction of 5,5'-dithiobis-(2-nitrobenzoic acid) (Ellman’s reagent, 
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DTNB; Sigma Aldrich; St. Louis, MO) with free thiols was exploited to evaluate this 
ratio. The absorbance of a dilute solution at 412 nm was recorded with a Perkin Elmer 
Lambda 35 UV/Vis spectrometer, and the results are directly proportional to the sulfur 
content in NAP-cyclam. L-cysteine (Sigma-Aldrich; St. Louis, MO) was used to generate 
a standard curve. 
5.3.5. HPLC Analysis of NAP-Cyclam 
High performance liquid chromatography (HPLC) was used to verify the molar ratio of 
NAP to cyclam in the final compound. Methanol (Chromasolv; 99.9%) and 
trifluoroacetic acid (TFA) were purchased from Sigma-Aldrich (St. Louis, MO). A 
Sonoma C18(2) 5 μ, 100 Å column manufactured by ES Industries (West Berlin, NJ) that 
measured 10 cm in length with a 3.2 mm inside diameter was used for all experiments. 
The HPLC system consisted of a Perkin Elmer Flexar PDA Plus detector, Series 200 
pump with a 20 μL injection loop, and Series 200 vacuum degasser (Waltham, MA). The 
mobile phase for all experiments was 30% water and 70% methanol with 0.1% TFA 
added to both components as a buffer. The flow rate in all experiments was 1 mL/minute. 
HPLC experiments were performed by first reacting the colorimetric thiol tag, Measure-
iT (Life Technologies; Grand Island, NY), with NAP-cyclam. Samples were prepared 
according to the manufacturer’s instructions and allowed to react for 20 minutes prior to 
each injection. The PDA detector was set to measure both 270 nm and 497 nm with a 
bandwidth of 10 nm. 
5.3.6. UV/Vis Analysis of SNAP-Cyclam 
NAP-cyclam and SNAP-cyclam were analyzed by UV/Vis spectroscopy in phosphate 
buffered saline (PBS) (Sigma-Aldrich; St. Louis, MO) (pH 7.4) at concentrations of 250 
μM on a Perkin Elmer Lambda 35 spectrometer (Waltham, MA). 
5.3.7. FTIR Analysis of (S)NAP-Cyclam 
Transmittance Fourier transform infrared spectroscopy (FTIR) was performed on an 
Analect Diamond 20 (Applied Instrument Technologies; Upland, CA). Samples were 
made by pressing 7 mm diameter potassium bromide pellets (Sigma Aldrich; St. Louis, 
MO) and running a transmittance scan on the sample (64 scans, 2 cm-1 resolution) under 
inert nitrogen. 
5.3.8. Quantitative Nitric Oxide Analysis 
Total NO release from SNAP-cyclam was directly measured via chemiluminescence 
detection with a Siever’s 280i Nitric Oxide Analyzer (Boulder CO). Phosphate buffered 
saline (PBS; pH 7.4), dichloromethane, and sodium ascorbate were obtained from Sigma-
Aldrich (St. Louis, MO). Chelex 100 Resin (sodium form) was purchased from Bio-Rad 
Laboratories (Hercules, CA). Copper (II) chloride was obtained from Alfa Aesar (Ward 
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Hill, MA). Tert-butyl nitrite was obtained from Acros Organics (Geel, Belgium). All 
measurements were made at room temperature. Approximately 50 mg of NAP-cyclam 
was nitrosated for each trial with clean tert-butyl nitrite for 6 hours in dichloromethane. 
This sample was diluted 1:10 in dichloromethane immediately prior to analysis. 1 mL of 
PBS and 100 μL of SNAP-cyclam were injected into a quartz reaction cell. 100 μL of 10 
mM CuCl2 and 300 μL of 100 mM sodium ascorbate were added to initiate release of NO 
from SNAP-cyclam. Once NO evolution returned to baseline levels, an additional 100 μL 
of 10 mM CuCl2 and 300 μL of 100 mM sodium ascorbate were added to ensure full 
decomposition of the RSNO. Theoretical calculations of the total NO present in the 
sample were compared to the total measured NO obtained through chemiluminescent 
detection. The total NO evolved was normalized to sample mass. 
5.3.9. Nitric Oxide Release from poly(ʟ-lactic acid) Film Samples 
Poly(ʟ-lactic acid) (PLLA) film samples were prepared by making a 4% (wt/wt) solution 
of PLLA (Natureworks, LLC; Minnetonka, MN) in chloroform (Sigma-Aldrich; St. 
Louis, MO). NAP-cyclam was added to the dissolved PLLA to produce solutions with 
final SNAP-cyclam concentrations of 30 mM and 68 mM. 100 μl of clean tert-butyl 
nitrite (Acros Organics; Geel, Belgium) was added to each solution followed by 20 μl of 
DBSA (Sigma-Aldrich; St. Louis, MO). The resulting solutions were solvent cast on 12 
mm diameter glass coverslips (VWR; Radnor, PA) using 100 μl of solution per sample. 
The films were allowed to dry under ambient conditions protected from light. 
Film samples were incubated at 37°C submerged in PBS (pH 7.4) (Sigma Aldrich; St. 
Louis, MO) for 91 days. NO released from the samples was measured with a Sievers 280i 
NOA at 37°C for 15 minutes on days 0, 15, 40, 62, and 91. Films were removed from the 
PBS solution during NO release measurements, and promptly returned after 15 minutes. 
A 385 nm (± 5 nm) light emitting diode (LED) (SSL-LXTO461UV1C; Lumex; Carol 
Stream, IL) was attached to the sample vial to promote NO release. The LED was 
powered with 73 mW at 27 mA and placed 5.2 cm above the sample. Four samples were 
evaluated per group. 
5.4. Results 
Cyclam has a total of 4 secondary amines that could be potential binding sites for the 
reaction of the self-protected NAP-thiolactone to covalently link to the ring19. It was 
confirmed through several analytical techniques that NAP-thiolactone reacts with the 
secondary amines present in the cyclam ring in a 1:1 molar ratio. 
5.4.1. Copper Chelation Analysis of NAP-Cyclam 
Cyclam will form a deep purple color when in solution upon chelation of Cu2+. The 
reaction of NAP-thiolactone with cyclam prevents the chelation of copper by NAP-
cyclam. Therefore, an absorbance based analysis technique was developed to confirm 
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that the reaction is occurring on the secondary amine sites present in the cyclam ring, 
thereby disrupting the ability of cyclam to chelate copper (II). Figure 5.1 shows the 
UV/Vis spectra over a range of 545–553 nm demonstrating the completion of the reaction 
required to form NAP-cyclam. In this approach, the magnitude of the absorbance 
corresponds to the degree of copper chelation. A reduction in absorbance at 545 nm 
between the 5 minute and 15 minute NAP-cyclam samples to background levels 
demonstrates a complete reaction between NAP-thiolactone and cyclam after 15 minutes. 
 
 
Figure 5.1. Reaction time determination of NAP-Cyclam. This figure shows the copper chelation 
analysis of NAP-cyclam. Cyclam (5 minutes; pink) and cyclam (240 minutes; green) demonstrate 
the characteristic absorbance change of copper loaded cyclam. NAP-thiolactone (5 minutes; black) 
does not demonstrate this phenomenon. NAP-cyclam (5 minutes; red) shows an increase in 
absorbance, while NAP-cyclam (15 minutes; gray) does not, indicating the completion of the 
reaction. 
5.4.2. Free Thiol Analysis of NAP-Cyclam 
The four secondary amine sites on the cyclam macrocycle make up to four molar 
additions of NAP-thiolactone possible. To determine the reaction stoichiometry of NAP-
cyclam, an Ellman’s test for free thiols present in NAP-cyclam was performed using 
UV/Vis spectroscopy. Figure 5.2 shows the calibration curve created using L-cysteine as 
the thiol standard. Three averaged samples of three independent NAP-cyclam samples 
(red, green, and blue) were plotted with standard deviations. The average molar ratio of 
thiol present was 0.80 ± 0.02:1. 
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Figure 5.2. Free thiol analysis of NAP-Cyclam. Free thiol analysis using Ellman’s reagent 
demonstrates a linear L-Cysteine standard curve. Three averaged samples of three independent 
NAP-cyclam samples (red, green, blue) show the experimental results. This data proves that the 
compound is composed of equimolar ratios of cyclam and NAP-thiolactone. 
5.4.3. HPLC Analysis of NAP-Cyclam 
Figure 5.3 shows the results of the HPLC elution of Measure-iT tagged NAP-cyclam. 
These results demonstrate a single elution peak (1.94 minutes) of the tagged compound, 
indicating a single molar ratio of NAP-cyclam exists. UV/Vis spectroscopy of the 
components used in the HPLC elutions are presented in Figure 5.4. The chromatograms 
of the respective eluents are provided in Figure 5.5 for positive identification. 
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Figure 5.3. Chromatography of NAP-Cyclam. Figure 5.3 shows the chromatograms of the Measure-
IT tagged NAP-cyclam and the respective components. As demonstrated in red (t = 1.94 minutes) 
NAP-cyclam exits the column as one entity, rather than multiple peaks, thus proving that an 
equimolar compound exists. The Measure-iT tag, when unreacted, exits the column after 9.72 
minutes. This peak is not presented in the Measure-iT tagged NAP-cyclam. Measure-IT buffer – 
Black; NAP-cyclam in buffer – Blue; Measure-IT tag in buffer – Green; Measure-IT tag reacted with 
NAP-cyclam in buffer – Red. Peaks - Red; 1.94 minutes: Green; 1.94 minutes, 9.72 minutes. 
 
Figure 5.4. UV/Vis analysis of chromatography components. Figure 5.4 shows the UV/Vis spectra 
of the components used in the HPLC evaluation of NAP-cyclam. Both the Measure-iT tag (pink; 
460 nm) and the Measure-iT tagged NAP-cyclam (red; 490 nm) show an absorption peak. This 
peak is also seen in the chromatogram of the components (Figure 7). 
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Figure 5.5. UV/Vis chromatograms of chromatography elution peaks. Figure 5.5 shows the 
chromatograms associated with the peaks in the HPLC elution of Measure-IT tagged NAP-cyclam. 
The peak profiles of the eluted peaks are similar to those in Figure 6, proving the identity of the 
components. Blue – Measure-IT tag (1.94 minutes); Black – Measure-iT tag (9.72 minutes); Green 
– Measure-iT tagged NAP-cyclam (1.16 minutes); Red – Measure-iT tagged NAP-cyclam (1.94 
minutes). 
5.4.4. UV/Vis Analysis of SNAP-Cyclam 
Solution phase samples were evaluated for spectral changes after nitrosation of NAP-
cyclam with tert-butyl nitrite in chloroform (Figure 5.6) to form the corresponding S-
nitrosothiol, SNAP-cyclam. The characteristic S-nitrosothiol peaks formed are seen in the 
UV/Vis spectrum of SNAP-cyclam at 349 nm (ε = ~340 M-1·cm-1) and 597 nm (ε = ~10 
M-1·cm-1). These peaks correspond to known absorption maxima of nitrosothiols reported 
as 330–350 nm (ε = ~103 M-1·cm-1) and 550–600 nm (ε = ~20 M-1·cm-1)16. This confirms 
that the thiolactone ring opens upon reaction with the secondary amines present in 
cyclam, exposing the thiol group. The free thiol can then be nitrosated to form the RSNO, 
S-nitroso-N-acetyl-D-penicillamine. Without a ring opening reaction exposing the 
primary thiol, the S-nitrosothiol could not form. 
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Figure 5.6. SNAP-Cyclam demonstrates characteristic UV/Vis absorption spectra. This figure 
shows the characteristic S-nitrosothiol peaks at 349 and 597 nm. These peaks have been 
previously reported to exist between 330–350 nm (ε = ~103 M-1cm-1) and 550–600nm (ε = ~20 M-
1cm-1). PBS – Black; 250 μM cyclam – Blue; 250 μM NAP-cyclam – Red; 250 μM SNAP-cyclam – 
Green. 
5.4.5. FTIR Analysis of (S)NAP-Cyclam 
In order to confirm the formation of SNAP-cyclam, FTIR was performed on pressed 
potassium bromide pellets of cyclam, NAP-thiolactone, NAP-cyclam, and SNAP-cyclam 
(Figure 5.7). Included for reference in the figure is the parent material to NAP-
thiolactone, N-acetyl-D-penicillamine. It can be seen that the secondary amine sites on 
the cyclam macrocycle (3180 cm-1 and 3272 cm-1) are significantly diminished (~8%) 
after the reaction with NAP-thiolactone. This evidence shows that the secondary amine 
sites on cyclam are the site of addition for NAP-thiolactone. The band at 2532 cm-1, 
corresponding to free thiols, indicates the successful ring opening reaction of NAP-
thiolactone. 
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Figure 5.7. FTIR analysis of (S)NAP-Cyclam. FTIR results illustrate the progression of the synthesis 
of (S)NAP-cyclam. Bands at 3180 cm-1 and 3272 cm-1 indicate the secondary amine sites in cyclam 
(blue line). These are significantly diminished in NAP-cyclam (green), identifying the secondary 
amines as the site of reaction for NAP-thiolactone. A single band in appearing in NAP-cyclam 
(green) at 2532 cm-1 indicates the presence of a free thiol, demonstrating the successful ring 
opening reaction of NAP-thiolactone. 
5.4.6. Quantitative Nitric Oxide Release 
The total NO released from SNAP-cyclam was determined to be 94. ± 0.023 % (n = 4) of 
the total theoretical NO available. The nitrosation resulted in 2.3 ± 0.056 μmols NO/mg 
of compound. 
5.4.7. Proposed Structure of SNAP-Cyclam 
Figure 5.8 shows the proposed chemical structure of SNAP-cyclam. The data suggests 
that the compound exists as a majority 1:1 molar ratio of NAP-thiolactone to cyclam. 
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Figure 5.8. Proposed structure of SNAP-Cyclam. Figure 5.8 shows the proposed structure of 
SNAP-cyclam, representing the equimolar ratio of components. The structure is approximated. 
5.4.8. Nitric Oxide Release from poly(ʟ-lactic acid) Films Containing SNAP-Cyclam 
In order to create a NO releasing polymeric material, SNAP-cyclam was blended into 
PLLA and cast into a thin film with final concentrations of 30 mM and 68 mM. Figure 
5.9 shows photolytic NO release averages for these film samples over 91 days at 37°C 
immersed in PBS (pH 7.4) (n = 4 per group). The characteristic green coloration of the 
RSNO was no longer perceptible after day 2. However, the sample released 
physiologically relevant amounts of NO upon stimulation with light. 
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Figure 5.9. Average nitric oxide release from SNAP-Cyclam loaded PLLA films. This figure shows 
the average NO released over 91 days from 30 mM and 68 mM SNAP-cyclam loaded PLLA films 
soaked in PBS (pH 7.4) at 37°C. Films were removed from solution and irradiated by a 385 nm 
LED to promote NO release from the films. 
5.5. Discussion 
Two primary types of NO donors undergoing extensive research and development for 
therapeutic applications are diazeniumdiolates and S-nitrosothiols. Although 
diazeniumdiolates have been investigated for many decades and hold promise for NO 
based therapies, they require a high pressure system pathway for nitrosation. To directly 
attach diazeniumdiolates to polymer backbones requires covalent attachment of a parent 
compound to the base polymer, which necessitates additional reaction steps to develop a 
functional material and will often fundamentally alter the mechanical properties of the 
polymer itself. Additionally, modifications to the NO release profile (which are often 
application specific and require extensive processing revisions) require relatively 
sophisticated and nuanced manipulations of the chemical pathway. These intrinsic 
limitations have accelerated the development of blended NO donors applicable to a wide 
variety of polymeric materials, where NO flux profiles can be altered by changing the 
quantity of compound. 
Here, we have developed a novel, stable NO donor, SNAP-cyclam, through a rapid, 
simple, and thermodynamically favorable reaction between NAP-thiolactone and cyclam. 
The compound exhibits high solubility in a wide range of solvents, including water. This 
property allows the new NO donor to be readily blended (and for NO release levels to be 
quickly modified) within a wide range of conventional polymeric materials for 
biomedical applications, surmounting the major recognized limitations of previous NO 
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donors. The release profile can be easily adjusted to optimize the flux of NO delivered by 
increasing the amount of SNAP-cyclam. 
As demonstrated in Figure 5.9, SNAP-cyclam incorporated into PLLA films and 
submerged in PBS exhibits consistent long-term, ion-mediated NO release at therapeutic 
levels. The estimated endogenous NO flux from intact, healthy endothelium is reported to 
be 0.5–4x10-10 mols·cm-2·sec-1 20. When the material is hydrated in PBS, metal ion 
mediated release (attributed to ion permeation from the PBS through the PLLA) as well 
as thermal mediated release contribute to the overall surface flux of NO obtained. The 
larger NO flux generated by the 30 mM sample after day 42 can be attributed to the lack 
of UV light penetration into the more opaque 68 mM sample. In clinical applications, 
light mediated mechanisms would be replaced by metal ion mediated or thermal mediated 
NO release methods. The stability of the NO donor and sustained release shown in vitro 
suggests that it may serve as a long-term NO donor, in vivo. 
To fully characterize NAP-cyclam, the compound’s molar ratio after formation were 
essential to determine the NO reservoir and predict the stability of the compound. FTIR 
results demonstrate direct involvement of the secondary amine sites on the cyclam 
macrocycle in the reaction, as evidenced by the disappearance of the characteristic 
secondary amine peaks at 3180 cm-1 and 3272 cm-1. FTIR also indicated a complete ring 
opening reaction of NAP-thiolactone by the presence of the free thiol band at 2532 cm-1. 
The proposed reaction mechanism for this product is has been previously alluded to in 
literature21-22. Reports of this reaction mechanism suggested that SN2 type nucleophilic 
substitution may be responsible for the formation of compounds between secondary 
amines and β-thiolactones21-22. Although the stoichiometry of NAP-cyclam was 
determined to be equimolar between NAP-thiolactone and cyclam, further work will be 
required to confirm the reaction mechanism. 
Due to the relative ease of synthesis of SNAP-cyclam and demonstrated stability under 
ambient conditions, this NO donor has potential applications in many medical device 
applications. The donor can be readily synthesized with few compounds: an appropriate 
solvent for the application, NAP-thiolactone, cyclam, an acid, and an appropriate 
nitrosating agent. This lends itself well to batch synthesis and mass production. Due to 
the donor’s solubility in many organic solvents and water, it is capable of being 
incorporated into a wide variety of medical polymers. To date, the donor has been 
successfully processed utilizing solvent casting, spin coating, electrospinning, and liquid 
atomization techniques (data not shown). In addition, the donor has been successfully 
sterilized by ethylene oxide treatment while encapsulated in polycaprolactone without 
loss of NO (data not shown). Ultimately, this donor is well suited to applications in 
conjunction with polymers (tubing, films, and constructs) and medical device coatings. 
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In applications for medical devices, the ideal storage and transportation conditions for a 
drug delivering material should include a wide margin of temperatures, and few, if any, 
special handling considerations. To this end, the material developed here has 
demonstrated stability at room temperature for over 12 months, with the only special 
handling precaution being protection from ambient light. This should not be taken as a 
deficiency of the material, as the requirement to keep it protected from light is easily 
provided for by the material's packaging in a clinical setting. 
Future development of this class of compounds should investigate the use of other 
macrocycles and secondary amine containing compounds. Elucidation of the mechanism 
of reaction may be possible by studying a secondary amine containing cyclic molecule 
(piperidine) or a porphyrin (porphine). 1,4,7,10-tetraazacyclododecane (cyclen), may 
exhibit similar properties as those of cyclam. To increase the molar ratio of NO available 
on a single macrocycle, and thus increase the amount of NO that can be stored within a 
polymer, bicyclam molecules could be evaluated23. 
5.6. Conclusion 
NO has many potential therapeutic applications due to its ubiquitous physiological 
prevalence. We have demonstrated that SNAP-cyclam, a novel NO donor formed in an 
equimolar reaction between the self-protected NAP-thiolactone and cyclam, can be 
formed in a straight forward manner. SNAP-cyclam demonstrated excellent stability after 
formation, and when blended with PLLA, also demonstrated sustained, long term 
delivery of NO under physiological conditions, in vitro. In addition to describing a 
promising NO donor, this work has demonstrated a novel reaction involving a commonly 
employed NO donor in research and clinical applications. This new approach has the 
potential to produce novel compounds with large NO reservoirs available for release over 
clinically relevant time periods. 
Long term in vivo evaluation of SNAP-cyclam will be required to determine its clinical 
relevancy. SNAP-cyclam holds promise as a valuable tool in the clarification of the 
biological effects of NO on physiological systems due to its ease of synthesis, 
incorporation into a wide range of polymers, and potential use as a clinical therapeutic. 
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Chapter 6: Transition Metal Mediated Release of Nitric Oxide (NO) from S-
nitroso-N-acetyl-D-penicillamine (SNAP): Potential Applications for 
Endogenous Release of NO on the Surface of Stents via Corrosion Products3 
 
6.1. Abstract 
Nitric oxide (NO), identified over the last several decades in many physiological 
processes and pathways as both a beneficial and detrimental signaling molecule, has been 
the subject of extensive research. Physiologically, NO is transported by a class of donors 
known as S-nitrosothiols. Both endogenous and synthetic S-nitrosothiols have been 
reported to release NO during interactions with certain transition metals, namely Cu2+ 
and Fe2+. Based on the electronic structure of the reported metals, alternative transition 
metals could be potential catalysts for the evolution of NO from RSNOs. 
 
Current coronary stents utilize biostable metals to provide mechanical support during 
coronary artery disease. However, these stents often fail due to in-stent thrombosis and 
restenosis. Alternatively, biodegradable stents have shown significant promise to reduce 
or eliminate both thrombosis and restenosis. One potential pathway to achieve this is by 
exploiting NO generation from endogenous RSNOs, caused by biodegradable stents 
releasing metal ions capable of decomposing RSNOs at the stent-blood interface. 
 
Here, we evaluate Pt2+, Fe2+, Fe3+, Mg2+, Zn2+, Mn2+, Co2+, Ni2+, and Cu2+ for their ability 
to generate NO from S-nitroso-N-acetyl-D-penicillamine (SNAP) under physiological pH 
conditions. Specifically, we report NO generation from RSNOs by three transition metal 
ions; Co2+, Ni2+, and Zn2+, which have not been previously reported to generate NO. 
Additionally, preliminary in vivo evidence of wires implanted in the rat arterial wall and 
circulating blood is presented which demonstrated inhibited thrombus formation after 6 
months. 
 
6.2. Introduction 
Nitric oxide (NO), a physiologically ubiquitous free radical gas, has been the center of 
extensive research over the past several decades after it was proven to be endothelial 
derived relaxing factor1. Though its functions in the physiological environment are 
extensive, NO’s most notable roles are within the realms of intracellular signaling2-3, 
vascular regulation4-5, and wound repair6. Due to NO’s state as a free radical gas, its half-
life in the physiological environment is short7-8. To allow physiological transport of this 
reactive molecule, NO is shuttled to specific targets in the form of endogenous S-
nitrosothiols (RSNOs). These compounds degrade to products of NO and a disulfide after 
transferring NO9. 
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Endogenous RSNOs, such as S-nitrosoalbumin, S-nitrosoglutathione, and S-
nitrosocysteine, are present throughout the body and in high concentrations in circulating 
blood10-11. Synthetic NO donors, such as S-nitroso-N-acetyl-D-penicillamine (SNAP) 
have been extensively studied as in vivo donors and are often used to replicate the 
physiological environment, in vitro12. RSNOs are also mediators of NO’s cytoprotective 
and cytotoxic effects6. This class of NO donors has been previously shown to degrade 
through several mechanisms including; photolytic cleavage of the S-N bond, transition 
metal mediated decomposition, and decomposition through interactions with ascorbate13. 
 
Of particular interest to us is the transition metal catalyzed release of NO14-15. Prior 
research has linked both Cu2+ and Fe2+, as well as Hg2+ and Ag+, as initiating NO release 
from both endogenous and synthetic RSNOs15-17. In the case of the copper mediated 
release of NO from RSNOs, Cu+, not Cu2+, is responsible for the decomposition and 
ultimate release of NO due to a thiolate reduction16. Interestingly, Co2+, Ni2+, and Zn2+ 
were reported as being incapable of promoting NO release through RSNO 
decomposition16, 18.  
 
NO possess significant potential for therapeutic applications within the vasculature due to 
the presence of constantly regenerating, free RSNOs in circulation19-21. Endogenously 
circulating ions essential for normal physiological function, such as Cu2+, Fe2+, Mg2+, and 
Zn2+, are also present in the blood. The physiological presence of both NO donor and 
catalyst could result in the discovery of clinical therapeutics, interventions, and devices 
which make use of these naturally occurring components and further the understanding of 
NO’s physiological roles. 
 
The potential applications of transition metal ion based NO production from endogenous 
RSNOs in the treatment and resolution of clinical pathologies are vast. One such 
application is the fabrication of bare metal, biodegradable stents. Annually, there are over 
445,000 deaths associated with coronary artery disease (CAD)22. CAD occurs after the 
formation of atherosclerotic lesions on the endothelium of coronary arteries, limiting the 
nutrient and oxygen supply to the heart. Coronary bare metal stent (BMS) failure rates 
vary between 20%–30%22. The common failure mechanisms for BMSs, typically made of 
stainless steel and nitinol23, are attributed to in-stent thrombosis and restenosis22, 24-25. 
There is evidence to suggest that NO generation at the stent-blood interface may be 
effective in the prevention and resolution of thrombosis and restenosis4, 26-27. 
 
Many transition metals and their alloys, including magnesium and zinc, have been shown 
to be bioabsorbable and have undergone development as materials for BMSs28-29. These 
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metals may evolve interfacial ions and degradation products with the potential to generate 
a NO flux at the luminal interface of the stent from circulating endogenous donors, 
thereby reducing or preventing stent failure by in-stent thrombosis and restenosis. 
 
To evaluate these ions for NO generation from RSNOs, SNAP was utilized to simulate 
endogenously present RSNOs in the circulating blood30. In addition to evaluating metal 
ions, wires, typical of the materials which might be implanted as BMSs, were dissolved 
and the resultant solutions were used to evaluate their ability to generate NO. In vivo 
images showing the biological response toward 4N zinc wires implanted into the aortic 
wall and lumen of rats after 6 months is presented. 
 
6.3. Materials & Methods 
6.3.1. ICP-OES Analysis 
70% nitric acid (≥ 99.999% trace metals basis) and metal standards (PtCl2, ZnCl2, FeCl2, 
FeCl3, MgCl2, CoCl2, MnCl2, NiCl2, and CuCl2) were obtained from Sigma Aldrich (St. 
Louis, MO) in 99.99%+ trace metals basis and/or anhydrous grades. Certificates of 
analysis were collected and inspected for each standard to ensure purity. Standards were 
made by dissolving each sample in 2% nitric acid to make 1 mM analytical standards of 
each metal ion. 
 
Wire samples of platinum (99.998% pure), zinc (99.99% pure), magnesium (99.9%+ 
pure), 4N iron (99.99%+ pure), and American Iron and Steel Institute (AISI) 316L 
stainless steel (Fe/Cr18/Ni10/Mo3) were obtained from Goodfellow Corporation 
(Coraopolis, PA). All samples had a diameter of 250 μm. Wire samples were cut to equal 
lengths (approx. 5 mm) and their masses were recorded before being placed into 10 mL 
of 2% nitric acid for 5 days to dissolve. Wires that did not fully dissolve after 5 days 
(platinum and 316L stainless steel) were removed from the solution, dried, and weighed 
to determine the mass lost while in solution. 5 mL of each sample was sent for analysis 
by inductively coupled plasma-optical emission spectrometry (ICP-OES) to Origin 
Analytical Inc. (Houston, TX). Origin Analytical processed all samples prior to analysis 
by diluting each by 10% in 5% aqua regia. 
 
6.3.2. Preparation of S-nitroso-N-acetyl-D-penicillamine (SNAP) 
SNAP was synthesized according to the procedure of Field, et. al31. N-acetyl-D-
penicillamine (NAP), methanol, and fuming hydrochloric acid (37%) were obtained from 
Sigma-Aldrich (St. Louis, MO). Sulfuric acid (95.0–98.0%) was obtained from EMD 
Chemicals (Gibbstown, NJ). Sodium nitrite (99.999% trace metals basis) was acquired 
from Alfa Aesar (Ward Hill, MA). 
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To prepare SNAP crystals, 1000 mg of N-acetyl-D-penicillamine were dissolved in 25 
mL of methanol and sonicated. Once dissolved, 15 mL of 1M HCl and 500 μL 
concentrated H2SO4 were added. Then, 724.5 mg of sodium nitrite was added to this 
solution and the solution was mixed until all solids had dissolved. The solution was 
allowed to react for one hour, developing a darkened, green color. The solution was then 
cooled in an ice bath for 45 minutes. All solvents were then removed by rotary 
evaporation, yielding a dark green, crystalline product. The crystals were ice cooled for 
30 minutes and isolated by vacuum filtration in deionized water, followed by 30 minutes 
under vacuum to ensure all solvents had been eliminated. 
 
6.3.3. Sample Preparation for Nitric Oxide Release Experiments 
Phosphate buffered saline (PBS), dibasic sodium phosphate (Na2HPO4), LC-MS Ultra 
Chromasolv water, and hydrochloric acid (99.999% trace metals basis) were obtained 
from Sigma Aldrich (St. Louis, MO). Sodium chloride (NaCl) was obtained from Macron 
Chemicals (Center Valley, PA). Potassium chloride (KCl) was sourced from EMD 
Chemicals (Gibbstown, NJ). Chelex 100 resin (sodium form) was obtained from Bio-Rad 
Laboratories (Hercules, CA). 
 
1 mM metal standards were made from the same stock salts as those sent for ICP-OES 
analysis using 10 mM PBS (138 mM NaCl; 2.7 mM KCl) made with LC-MS Ultra 
Chromasolv water and treated with Chelex 100 resin to remove metal impurities. The pH 
of the resulting solution was adjusted to 7.4 through the dropwise addition of 1M HCl as 
measured by an electrochemical pH probe (Symphony SB80PI; VWR; Radnor, PA). 
Similarly, a 1 mM SNAP solution was prepared using the 10 mM PBS for the ensuing 
NO release experiments. SNAP solutions were freshly made every 2 hours during the 
experiments. 
 
Wire samples were used as prepared from the ICP-OES analysis to facilitate dissolution 
of the solid wire samples. A 100 mM PBS solution (138 mM NaCl; 2.7 mM KCl) made 
in LC-MS Ultra Chromasolv water was prepared and treated with Chelex 100 resin. The 
pH of the resultant buffer was adjusted to 7.4 through a dropwise addition of 1M HCl as 
measured by an electrochemical pH probe (Symphony SB80PI; VWR; Radnor, PA). A 1 
mM SNAP solution was prepared using this 100 mM phosphate buffer for use in the wire 
sample NO release experiments. SNAP solutions were freshly made every 2 hours during 
the experiments. 
 
6.3.4. Nitric Oxide Release 
The potential of the metal standards and dissolved wire samples to release NO were 
evaluated by measuring the NO generated from 2 mL of 1 mM SNAP solution when 100 
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μL of either the standards or samples were injected. The final concentration of SNAP 
used in the experiments was 2.73 mM, and the concentration of the metal standards was 
90.9 μM. The final pH of the metal standards was 7.4, while the wire samples had a final 
pH ranging between 6.2–6.9. To measure NO release by chemiluminescence, a Siever’s 
280i Nitric Oxide Analyzer (NOA) (Boulder, CO) was used to collect the NO release 
data. Quartz sample cells were connected to the NOA, while ambient air was swept 
through the sample cell to carry generated NO to the reaction chamber. A stir bar was 
added to the sample cell to agitate the solution. All experiments were conducted with the 
sample cell protected from ambient light. During experiments, SNAP was allowed to 
equilibrate for 2 minutes to obtain a representative baseline prior to addition of the metal 
ion standard/sample. 100 μL of the standard or sample was injected at 2 minutes using a 
Hamilton glass syringe (Reno, NV) through a septum, and sample data was collected for 
a further 8 minutes. After 8 minutes, 100 μL of 1 mM CuCl2 was injected as a positive 
control. Metal ion standards were tested in triplicate (n = 3), while metal wire samples 
had four replicates (n = 4) evaluated. 
 
6.3.5. Preliminary Platinum & Zinc Wire In Vivo Studies 
Pure platinum (99.998%) and 4N zinc (99.99%+) wire with diameters of 250 μm were 
obtained from Goodfellow Corporation (Coraopolis, PA). Absolute ethanol was obtained 
from Pharmco Aaper (Brookfield, CT). Adult Sprague-Dawley rats were used for all in 
vivo experiments (Harlan Laboratories; Indianapolis, IN). 
 
All animal work was approved by Michigan Technological University’s Internal Animal 
Care and Use Committee (IACUC; #L0182). The surgical procedure has been previously 
published32. 4 mm (2 hours) and 10 mm (6 months) lengths of zinc wire were cut prior to 
implantation and stored in 70% ethanol for 30 minutes until use. Rats were anesthetized 
with 2.1% inhaled isoflurane in oxygen gas. One subset of samples was implanted into 
the abdominal aorta wall, while another was implanted into the blood contacting lumen. 
The wires were carefully pushed through the adventitial layer of the abdominal aortic 
tissue and advanced within the arterial wall along the full length of the specimen. 
Platinum and zinc wires were implanted for 2 hours to assess early stage thrombus 
formation. Zinc wires were implanted for 6 months in both the arterial wall and lumen to 
assess long term performance, in vivo. 
 
Animals were sacrificed at 2 hour and 6 month end points by increasing the inhaled 
isoflurane concentration from 2.1% to 5% after the animals were fully anesthetized. The 
diaphragms were punctured, and the hearts were removed to ensure death.  
 
Platinum and zinc samples collected at the 2 hour time point were carefully excised with 
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a transverse arterial incision to ensure that the neotissue formed on the wires was 
undisturbed. Samples were dehydrated in a graded ethanol series and mounted on 
conductive carbon tape. Samples were coated with 5 nm of Pt/Pd with a Hummer 6.2 
sputter coater (Anatech, Ltd.; Denver, NC). Samples were stored in a desiccator prior to 
imaging. Imaging was performed on a Hitachi S4700 field emission scanning electron 
microscope (5kV accelerating voltage, 10 μA beam current; Tokyo, Japan).  
 
The implant sites of the 6 month zinc samples were isolated and the abdominal aortas 
containing the entire specimen were excised. Samples were placed into Polyfreeze 
freezing medium (Sigma-Aldrich; St. Louis, MO), snap frozen in liquid nitrogen, and 
stored at −80 °C until cryosectioning. 8 μm sections were collected on Histobond slides 
(VWR; Radnor, PA) with a Microm HM 550 (Microm International GmbH; Walldorf, 
Germany). 
 
Hematoxylin & Eosin staining was performed on the 6 month zinc wire samples to assess 
the performance of the implanted specimens. All components were purchased from 
Sigma Aldrich (St. Louis, MO) with the exception of the Gill’s no. 3, purchased from 
Leica Biosystems (Buffalo Grove, IL). Sections were fixed immediately prior to 
cryosectioning by immersing them in -20°C chilled ethanol for 60 seconds. Samples were 
washed in three changes of PBS (pH 7.4) for 5 minutes each, followed by a wash in 
deionized water for 5 minutes. Sections were then placed in Gill’s no. 3 for 5 minutes. 
The slides were then differentiated by dipping into dilute hydrochloric acid (pH 2). Once 
differentiated, the slides were placed into deionized water for 1 minute. The blued 
samples were placed into two changes of 95% ethanol for 5 minutes each. Eosin Y 
(0.25%) counterstained the sections for 30 seconds, prior to being dehydrated in absolute 
ethanol and cleared in xylene substitute. The samples were then mounted and imaged on 
an Olympus BX-51 microscope (Waltham, MA). 
 
6.4. Results 
6.4.1. ICP-OES Analysis of Metal Standards and Wire Samples 
ICP-OES results coincide with the reported data from the certificates of analysis for all 
standards. As shown in Table 6.1, all 1 mM wire standards contained only their parent ion 
in significant quantities. The metal ion composition of the wire samples are shown in 
Table 6.2. Analysis showed zinc, iron, and magnesium solutions contained only their 
parent ion present in solution. Platinum did not show any significantly detectable 
platinum ion in solution. 316L stainless steel, though composed of iron, cobalt, nickel, 
and manganese, showed only trace quantities of iron in solution. 
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Table 6.1. ICP-OES analysis of metal ion standards. Table 6.1 summarizes the ICP-OES results 
for the metal ion standards. Analytical standards were made as 1 mM solutions in 2% nitric acid. 
Values are reported in ppm (mg/kg). A blank cell indicates that no data was reported for the method. 
 PtCl2 ZnCl2 MgCl2 FeCl3 CoCl2 NiCl2 MnCl2 CuCl2 
Pt 153        
Zn < 0.100 52.6 < 0.100 < 0.100 < 0.100 0.209 < 0.100 < 0.100 
Mg < 0.100 < 0.100 20.4 < 0.100 < 0.100 < 0.100 < 0.100 < 0.100 
Fe    50.6     
Co     4.47    
Ni      45.3   
Mn       4.56  
Cu        47.9 
 
 
Table 6.2. ICP-OES analysis of metal wire samples. Table 6.2 summarizes the ICP-OES results 
for the metal wire samples. Values are reported in ppm (mg/kg). A blank cell indicates that no data 
was reported for the method. 
 Platinum Zinc Magnesium Iron 316L Stainless Steel 
Pt      
Zn  222.5 < 0.100 < 0.100  
Mg   55.15   
Fe < 0.100   243.3 < 0.100 
Co      
Ni      
Mn      
Cu      
 
6.4.2. Nitric Oxide Release in Metal Standards  
Figure 6.1 shows the NO generated from the SNAP solution under physiological pH and 
ionic strength from Pt2+, Fe2+, Fe3+, Mg2+, Zn2+, Mn2+, Co2+, Ni2+, and Cu2+ via 
chemiluminescence. Figure 6.2 shows a magnified view with the copper standard 
omitted. Figure 6.3 shows Figure 6.2 plotted with standard deviations. In this work, a 
level of NO release 150% of the baseline value will be established as significant. The two 
ions reported in literature to generate NO from RSNOs, Cu2+ and Fe2+, both initiated NO 
release upon injection into the SNAP solution. Co2+, Ni2+, and Zn2+ also initiated release 
of NO from RSNOs. Pt2+, Fe3+, Mg2+, and Mn2+ did not demonstrate any significant 
release of NO.  
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Figure 6.1. S-nitrosothiol decomposition by metal ion standards. Metal ion standards were 
evaluated for their ability to evolve NO from RSNOs. Copper(II), (blue), is known to cause RSNO 
decomposition and is shown here as a positive control. Iron(II) (red) has been previously reported 
to cause NO generation from RSNOs. Nickel(II) (purple) and zinc(II) (light green) demonstrated NO 
release at levels similar to those of Iron(II). Cobalt(II) (cyan) is also observed to be elevated above 
the baseline. Notably, iron(III) (burgundy) and magnesium(II) (gray) did generate NO release over 
the baseline. As expected, platinum(II) (pink) was also inactive. All samples were injected at 2 
minutes. Copper(II) was injected after 10 minutes to demonstrate the presence of RSNO in the 
sample. The pH of the solution was 7.4. The plots represent n = 3 averaged values per sample. 
This data is available in the supporting information related to this article with standard deviations 
plotted for each sample. Legend: Blank-black; Platinum(II)-pink; Iron(II)-red; Iron(III)-burgundy; 
Magnesium(II)-gray; Zinc(II)-light green; Manganese(II)-dark green; Cobalt(II)-cyan; Nickel(II)-
purple; Copper(II)-blue. 
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Figure 6.2. Decomposition of S-nitrosothiols by metal ion standards. Figure 6.2 shows an enlarged 
view of figure 6.1 to enhance the detail of the ions of interest. Copper(II) has been omitted from this 
figure for simplicity. In this figure, iron(II), nickel(II), and zinc(II) are seen to be more clearly 
separated than in the previous figure. All samples were injected at 2 minutes. Copper(II) was 
injected after 10 minutes to demonstrate the presence of RSNO in the samples. The plots represent 
n = 3 averaged values for each sample. This data is available in the supporting information related 
to this article with standard deviations plotted per sample. Legend: Blank-black; Platinum(II)-pink; 
Iron(II)-red; Iron(III)-burgundy; Magnesium(II)-gray; Zinc(II)-light green; Manganese(II)-dark green; 
Cobalt(II)-cyan; Nickel(II)-purple. 
 
Figure 6.3. Decomposition of S-nitrosothiols by metal ion standards - statistics. Figure 6.3 shows 
figure 6.2 with standard deviations plotted for each sample. n = 3 per sample. Copper(II) has been 
omitted from this figure. All samples were injected at 2 minutes. Copper(II) was injected after 10 
minutes to demonstrate the presence of RSNO in the sample. The plots represent n = 3 averaged 
values per sample. Legend: Blank-black; Platinum(II)-pink; Iron(II)-red; Iron(III)-burgundy; 
107 
 
Magnesium(II)-gray; Zinc(II)-light green; Manganese(II)-dark green; Cobalt(II)-cyan; Nickel(II)-
purple. 
6.4.3. Nitric Oxide Release in Metal Wire Samples 
The NO generation from solutions of the metal wire samples can be seen in Figure 6.4. 
The same figure with plotted standard deviations is represented in Figure 6.5. Again, NO 
release exceeding 150% of the baseline value was deemed to be significant. Zinc and 
316L stainless steel wires demonstrated elevated release of NO over the 150% threshold. 
Magnesium, iron and platinum generated NO from SNAP at levels higher than the 
baseline, but not above the 150% threshold. 
 
 
Figure 6.4. Decomposition of S-nitrosothiols by metal wire samples. Metal wires were evaluated in 
a similar manner as their respective metal standards. As observed in the standards, the zinc wire 
(light green) used here shows elevated release over the 2% nitric acid blank. 316L stainless steel 
(yellow) is also elevated. Due to the acid used to dissolve the wires, the pH of the samples varied 
between 6.20 and 6.90. All samples were injected at 2 minutes. Copper(II) was injected after 10 
minutes to demonstrate the presence of RSNO in the sample. The plots represent n = 4 averaged 
values per sample. This data is available in the supporting information related to this article with 
standard deviations plotted for each sample. Legend: Blank-black; Platinum-pink; Iron-red; 
Magnesium-gray; Zinc-light green; 316L stainless steel-yellow. 
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Figure 6.5. Decomposition of S-nitrosothiols by metal wire samples - statistics. Figure 6.5 shows 
figure 6.4 plotted with standard deviations for each sample. n = 4 per sample. All samples were 
injected at 2 minutes. Copper(II) was injected after 10 minutes to demonstrate the presence of 
RSNO in the sample. The plots represent n = 4 averaged values per sample. Legend: Blank-black; 
Platinum-pink; Iron-red; Magnesium-gray; Zinc-light green; 316L stainless steel-yellow. 
6.4.4. In Vivo Zinc & Platinum Wire Implants 
In vivo implantations of zinc and platinum wires into the bloodstream are represented in 
Figure 6.6. As can be seen in Figure 6.6A, implanted platinum wires showed a significant 
thrombotic response with full occlusion of the implant surface. Platinum wires 
demonstrated extensive cellular and fibrin coverage. In contrast, the implanted zinc wires 
(Figure 6.6B) showed minimal cellular deposition leaving the majority of the implant 
surface free of material. In addition, individual cells can be identified on the zinc wire 
samples whereas no individual cells were discernable on the platinum wire samples. 
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Figure 6.6. Images of intraluminal platinum and zinc wire implants. Figure 6.6 shows representative 
images of the relative differences in thrombotic response between platinum (A) and zinc (B) wires 
implanted into the bloodstream of a rat. 
Figure 6.7 shows a typical result of the 6 month zinc wire luminal implant study. The 
green asterisks denote the corrosion layer in Figure 6.7A and the displaced wire in Figure 
6.7B. The wire implanted into the adventitia of the artery (Figure 6.7A) shows signs of 
substantial encapsulation and increased cellular density. Necrotizing, apoptotic cells and 
nucleic disparity is evident. Minimal cell penetration into the dense corrosion layer 
characterizes the sample shown in Figure 6.7A. 
 
The intra-luminal implant (Figure 6.7B), exposed to flowing blood throughout the trial, 
shows little thrombus with an intact neo-endothelium (red arrows). The corrosion layer32, 
denoted by yellow arrows in Figure 6.7B, demonstrates a loose, low density structure 
with signs of cellular infiltration and significant extracellular matrix remodeling. The 
corrosion layer consists of a thin, external calcium/phosphate layer while internally a 
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mixture of zinc oxide and zinc carbonate dominate the environment32. The yellow 
asterisk highlights the intact media of the artery. 
 
 
 
Figure 6.7. Histology of intraluminal zinc wire implants. This figure shows a representative result 
for 4N zinc wires implanted into the wall (A) and the luminal space (B) of a rat abdominal aorta. 
The green stars identify the corrosion layer (A) and wire (B). The yellow star identifies the medial 
layer of the native artery. The yellow arrows in B identify mononuclear cells within the corrosion 
layer. Red arrows denote neo-endothelium. The open space beyond the red arrows is the arterial 
lumen. The open space between the wire and corrosion layer in B is an artifact of sectioning 
whereby the wire was displaced from the corrosion layer. The scale bar represents 100 μm. 
6.5. Discussion 
The combination of manufacturer certificates of analysis and ICP-OES analysis of 
prepared solutions indicates that all standards, with the exception of NiCl2, used in these 
experiments were free of any other interfering ions. NiCl2 showed trace amounts of Zn, 
though the level was more than two orders of magnitude lower than the corresponding 
ZnCl2 sample. Importantly, Cu2+ and Fe2+, known to be strong catalysts of NO generation 
from RSNOs, were not present except in their respective ion/wire samples. Wire samples 
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were also free from undesirable transition metal ions. The solutions of the platinum and 
stainless steel wires showed that none of the dissolved ions tested (Pt2+, Fe2+, Fe3+, Mg2+, 
Zn2+, Mn2+, Co2+, Ni2+, and Cu2+) were present. Chelex 100 resin treatment of the 
phosphate buffers removed potential transition metal ion contaminates, such as 
extraneous Cu2+ and Fe2+. Care was taken to avoid contamination at all points in the 
experimental work to eliminate NO generation from ions other than the primary transition 
metal present in the specific test solution. 
 
Current theories speculate that NO is carried by endogenous RSNOs and is delivered 
through trans-nitrosation reactions13. However, the mechanism of this process and the 
role transition metals play is not currently well understood9, 33. 
 
Identification of Co2+, Ni2+, and Zn2+ as reactive ions capable of generating NO from 
RSNOs is an important step in harnessing NO for investigations into its biological 
relevance, but also for clinical applications and therapies. Elucidating a mechanism of 
action for the transition metal catalyzed release of NO from RSNOs would represent a 
significant advancement in the overall understanding of the physiological transport, 
behavior, and mechanisms responsible for NO’s inherent biological activity. 
 
Not previously reported to induce NO release, Zn2+ has the potential to alter strategies in 
the fabrication of metal implants due to its proclivity to generate NO from RSNOs, 
demonstrated in both zinc ion standards and zinc wire samples. NO demonstrates great 
potential in the treatment and resolution of many clinical outcomes associated with 
thrombosis, intimal hyperplasia, and restenosis through control of platelet aggregation 
and inhibition of smooth muscle cell proliferation4, 26-27. 
 
Though some of the ions evaluated here demonstrated release of NO from RSNOs, it is 
important to note that on average, they were one order of magnitude lower than those of 
Cu2+. Though significantly lower, this reduced level of NO release from RSNOs by 
alternative transition metals could be advantageous in vivo when applied to clinical 
devices. Estimated values for endogenous NO flux from intact, healthy endothelium is 
reported to be 0.5–4x10-10 mols·cm-2·sec-1 as being the requisite therapeutic flux for 
endothelial cells34. In the potential application presented here, the endothelial lining of 
the vascular lumen is in direct contact with the stent following deployment. This 
represents an ideal circumstance in which the degrading surface releases metal ions 
directly into a replenishing supply of endogenous RSNOs. 
 
We have demonstrated that zinc, a material currently undergoing development for use in 
biodegradable bare metal stents32, is capable of eliciting NO from RSNOs. Coupled with 
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its favorable degradation characteristics32, zinc has significant potential in this 
application. Though the available physiological concentration of RSNOs in the body is 
likely significantly reduced from the levels used above, the release of physiologically 
relevant NO from the interaction between Zn2+ and endogenous RSNOs is possible. 
 
The platinum and zinc wire samples shown in Figure 6.6 exhibit vastly different 
thrombotic responses after only 2 hours of in vivo implantation into the flowing blood of 
rats. In the case of the platinum wires, extensive thrombus deposition was prevalent, 
completely occluding the surface of the wire. In general, the platinum wire samples 
exhibited this active coagulation response resulting in complete coverage including an 
observable fibrin mesh, cellular adhesion, and complete coating of the surface. 
Alternatively, the zinc samples presented a less extensively covered surface and a 
response exhibiting fewer signs of highly activated intrinsic coagulation. Based on the 
results of this work, a later term study was conducted on 4N zinc wires to assess their 
long term performance when exposed to flowing blood and implanted in the vascular 
wall of rats for 6 months. 
 
The 6 month implanted zinc wires shown in Figure 6.7 demonstrate remarkable 
differences between the biological response observed in the vascular wall and in flowing 
blood. Figure 6.7A presents a picture of chronic inflammation, apoptosis, and necrosis, 
with little if any resolution of the initial insult. Figure 6.7B appears to consist of mainly 
healthy tissue, with active removal of the degradation products and a reformed 
endothelium with significant progress towards resolution. As a potential candidate 
material for bare metal stent struts, endogenous production of NO from zinc would be a 
beneficial attribute for the control over the immune response. 
 
The differences in the biological response observed during the in vivo studies are 
potentially attributable to low level NO generation from endogenous RSNOs present in 
the blood, with supporting data for this theory available from the in vitro results. It is 
important to note that the kinetics of diffusion for the circulating endogenous RSNOs 
attributed to these results are location dependent. Rates of RSNO replenishment within 
circulating blood will be more rapid than in the vessel wall, resulting in a higher level of 
NO generation within the flowing blood16, 35-36. Further studies will be required to 
ascertain whether NO is solely responsible for the observed results. 
 
6.6. Conclusion 
This work demonstrates the potential for alternative transition metal ions; Co2+, Ni2+, and 
Zn2+, to generate NO from endogenous RSNOs under physiological conditions. Fe3+, 
Mg2+, Mn2+, and Pt2+ did not demonstrate significant release. The wire samples represent 
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a clinically relevant application of this novel information for applications including 
bioabsorbable metal stents, device coatings, and targeted NO therapies. While this study 
investigated some of the more common transition metals, many more remain to be 
evaluated. 
 
While the in vivo data presented highlights one possible application and potential 
explanation for the observed results, a multitude of applications exist for biocompatible 
metal ions capable of generating NO from endogenous sources. In these capacities, NO 
generation at or near an implant surface can potentially maintain control over device 
failure through common rejection pathways such as thrombosis, chronic inflammation, 
intimal hyperplasia, and restenosis. 
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Chapter 7: Summary and Future Directions 
 
7.1. Conclusions and Summary of Findings 
The work presented within this document is intended to approach the problems associated 
with current small diameter vascular grafts through engineering approaches by 
fabricating hybrid constructs with targeted components. This methodology provides 
flexibility in tailoring aspects of the mechanical properties to better match the native 
architecture. Additionally, a hybrid engineered construct gleans benefits of both the 
native elastin, with the ability to easily incorporate drug releasing mechanisms in close 
proximity. 
The development and production of thrombotic and neointimal hyperplasia resistant 
small diameter vascular grafts has been outlined in chapter 4. These constructs were 
fabricated by exploiting the non-thrombogenic properties of native elastin matrices as 
blood contacting surfaces. The results indicated promising performance of the blood 
contacting layer, with minimal thrombosis evident. Additionally, mechanical testing of 
the graft revealed an elastic moduli which closely matched that of a native coronary 
artery. Burst pressure testing of the construct also provided ample evidence for the graft’s 
suitability, exceeding the physiological requirements. The grafts demonstrated stability 
under ambient conditions for over 6 months when stored at room temperature, furthering 
their potential for clinical success.  
Chapter 5 delved into the synthesis and performance of a novel macrocyclic NO donor, 
SNAP-cyclam, which demonstrated excellent stability and controlled release of NO 
through several mechanisms. The compound maintains a straight forward synthesis route 
using a macrocyclic base, which is in current use as a cancer therapeutic and drug 
delivery agent. During development, SNAP-cyclam revealed a novel reaction mechanism 
which could result in the discovery of a multitude of novel NO donors, all with potential 
research and clinical relevancy. Coupled with a novel release mechanism, SNAP-cyclam 
is poised for a significant impact on the NO community. 
While the photolytically catalyzed release of NO from potential donors is an invaluable 
tool in diagnostics and research, its application in clinical practice is severely hindered in 
all but the most superficial applications. Chapter 6 presents data demonstrating metal 
catalyzed release of NO from a common NO donor, S-nitroso-N-acetyl-D-penicillamine. 
Previous research had indicated the efficacy of two transition metal ions, copper and iron, 
as being capable of metal catalyzed NO release. The data presented here indicates that 
additional transition metals; cobalt, nickel, and zinc, are also capable of causing RSNO 
decomposition and resultant NO release. Zinc is a bioabsorbable material already known 
118 
 
to be physiologically present and biocompatible, and its incorporation into NO releasing 
scaffolds may provide a route to precisely alter the NO flux generated by an implant. 
7.2. Future Directions 
The body of work presented thus far has led to a culmination of research which attempts 
to address the current shortcomings in small diameter vascular grafts; namely, thrombosis 
and late stage neointimal hyperplasia. In addition, this research has shown a practical 
route to utilize native elastin scaffolds to produce shelf stable, small diameter vascular 
grafts. The chapters of this document describe the three elements of a hybrid, engineered 
vascular construct. As the development of the individual components has been 
completed, the fabrication of a multi-component, hybrid engineered construct is now 
feasible. 
This engineered graft will be constructed in a manner similar to the native artery, with an 
elastin derived layer comprising the intima of the vessel, providing a non-thrombogenic 
blood contacting surface. The media will be comprised of several alternating polymeric 
layers, containing either zinc or SNAP-cyclam, which provide active protection against 
thrombosis and neointimal hyperplasia. The adventitia of the vascular construct will 
provide mechanical support and be composed of an elastic polyether urethane, 
electrospun fiber mat. 
The native elastin derived from rat thoracic aortas performed admirably, however their 
size and elastin content is not optimal for translation to clinical use. The use of an 
alternative vessel from a larger donor is necessary to more optimally match the size and 
properties of the intended human recipients. Ideally, this vessel would be readily 
available and easily isolated. Improvements on the performance of the current graft can 
be made through the retention of collagens in the adventitial zone, permitting better 
handling and mechanical characteristics. Additionally, the use of alternative donor 
material high in elastin, such as the porcine internal mammary artery, may significantly 
improve graft performance by reducing the quantity of immunogenic collagen near the 
luminal surface. 
SNAP-cyclam, presented within chapter 5, has significant potential for use in NO based 
therapies and research applications, as it is highly soluble in many common organic 
solvents and can be readily incorporated into polymer constructs as a blended material. 
Preliminary work with SNAP-cyclam embedded in electrospun polycaprolactone has 
demonstrated promising results, in vivo. Further studies will be required to assess its 
performance. Following the same reaction scheme as SNAP-cyclam, alternative 
secondary amine based S-nitrosothiol donors have been produced and are awaiting 
evaluation.  
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Information gleaned from the work presented in chapter 6 presents new possibilities for 
the release of NO from both endogenous and synthetic RSNOs. The three identified ions 
are applicable to a wide range of applications: as a NO release mechanism in vascular 
grafts, as bare metal stents capable of generating NO from endogenous S-nitrosothiols, or 
as research tools to better understand the roles and relationships of NO in the 
physiological environment. Importantly, zinc is undergoing development as a 
biodegradable vascular bare metal stent material1-6. The newly discovered ability of zinc 
to elicit S-nitrosothiol decomposition provides new pathways to the prevention of 
thrombosis, neointimal hyperplasia, and restenosis in medical implants. 
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